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Schizophrenia is a serious mental condition which interferes a normal life of a patient with 
schizophrenia diagnosis and imposes a substantial burden on caregivers. Schizophrenia is not 
fatal itself as a disease but it is involved with high risk of suicide, various types of adverse 
events caused by treatment medications, high costs of treatments including inpatient care and 
rehabilitation wards and substantial indirect costs. Therefore, if a novel antipsychotic medication 
is able to reduce significantly the schizophrenia symptoms without adverse events, the 
medication can alleviate social burden in a society as well as severe pain to the patients and the 
caregivers. There are tens of antipsychotic medications for schizophrenia being sold in Norway. 
This study is aimed at finding an optimal choice in terms of cost-effectiveness among the most 
popular antipsychotics for schizophrenia, olanzapine and risperidone. 
 
All that glitters is not gold. I believe that discerning the gold is a duty of a health economist and 
this master thesis work was one part of stepping stones leading me to become the health 
economist. I would like to thank my supervisor, Eline Aas who has been supporting me with her 
knowledge, passion and warm heart since I began this master thesis in May in 2008. Thanks for 
Ivar Sønbø Kristiansen with constructive advices on my thesis. Lastly, thanks for infinite 
supports of my parents, family and friends in Korea.  
 
My supervisor was Eline Aas, PhD., at the Institute of Health Management and Health 









April in 2009 in Oslo. 
 
 2
TABLE OF CONTENTS 
 
FOREWORD……………………………………………………………………..... 2
ABBREVIATIONS AND ACRONYMS………………………………………..... 5
ABSTRACT………………………………………………………………………… 6
  
Chapter 1  
INTRODUCTION………………………………………………………………..... 7
  
Chapter 2  
BACKGROUND…………………………………………………………………… 9
2.1. Symptoms……………………………………………………………………... 9
2.2. Diagnosis and prognosis………………………………………………………. 10
2.3. Epidemiology and risk factors………………………………………………… 11
2.4. Outcome measurements………………………………………………….....…. 13
2.5. Treatments…………………………………………………………………….. 14
2.6. Olanzapine and risperidone…………………………………………………… 15
  
Chapter 3  
RESEACH QUESTION…………………………..……………………………….. 17
3.1. Literature review………………………………………………………………. 17
3.2. Economic evaluation…………………………………………………………... 18
3.2.1. CEA, CUA and CBA……………………………………………………... 18
3.2.2. Decision making in CEA…………………………………………………. 19
3.2.3. Sensitivity analysis……………………………………………………….. 21
3.3. Research question……………………………………………………………... 23
  
Chapter 4  
METHODS…………………………………………………………………………. 24
4.1. A decision analytic model……………………………………………………... 24
 3
4.2. Model description……………………………………………………………... 25
4.2.1. The acute stage (from the baseline to the 16th week)……………………... 26
4.2.2. The maintenance stage (from 16th week to 5th year)……………………… 27
4.3. Clinical effectiveness and probabilities……………………………………….. 29
4.4. Health care resources………………………………………………………….. 32
4.4.1. Drug cost………………………………………………………………….. 32
4.4.2. Community based care cost………………………………………………. 33
4.4.3. Residential care cost……………………………………………………… 34
4.4.4. Hospitalized care cost…………………………………………………….. 35
4.4.5. Suicide-related cost……………………………………………………….. 36
4.4.6. Drop out cost……………………………………………………………… 36
  
Chapter 5  
RESULTS…………………………………………………………………………... 38
5.1. Costs and health consequences………………………………………………... 38
5.2. Sensitivity analysis……………………………………………………...…….. 39
5.2.1. One-way sensitivity analysis………………………………...…………… 40
5.2.2. Tornado diagram………………………………………………………….. 41
5.2.3. Two-way sensitivity analysis……………………………………………... 47
5.2.4. One-way sensitivity analysis on adequate respond parameters…………... 47
5.3. Probability Sensitivity Analysis using Monte Carlo simulation………………. 49
 
Chapter 6  









ABBREVIATIONS AND ACRONYMS 
 
AIMS Abnormal Involuntary Movements Scale  
APA American Psychiatric Association 
CBA Cost-Benefit Analysis   
CBC Community Based Care 
CEA Cost-Effectiveness Analysis 
CGI Scale Clinical Global Impression Scale  
CPI Customer Price Index 
CUA Cost-Utility Analysis 
DALYs Disability Adjusted Life-Years 
DRG code Diagnosis-Related Group code 
DSM-IV Diagnostic and Statistical Manual of Mental Disorders, 4th Edition  
EPSs Extrapyramidal Symptoms 
ESRS Extrapyramidal Symptom Rating Scale  
GAF Scale  Global Assessment of Functioning Scale  
HAI Hillside Akathisia scale 
HTA Health Technology Assessment 
ICD-10 The International Statistical Classification of Diseases and Related Health Problems 10th Revision 
ICE Incremental Cost Effectiveness 
ICER Incremental Cost Effectiveness Ratio 
NMB Net Monetary Benefit 
PANSS Positive and Negative Symptom Scale 
PSA Probability sensitivity analysis 
QALYs quality-adjusted life-years 
QOL Quality of Life 
RCTs Randomized Clinical Trials 
SF-36 36-Item Short-Form Health Survey  
SPS Social Performance Schedule 
TP Willingness To Pay 




Background: Schizophrenia is a major public health problem throughout the world and known 
to be a major cause of disability. Antipsychotic medications are the mainstay of treatment for 
schizophrenia and olanzapine and risperidone are popular choices among atypical antipsychotics 
in Norway. Despite of the high number of prescribing olanzapine, however, cost-effectiveness 
of olanzapine versus risperidone is still debated. 
 
Methods: A decision analytic model combined of a decision tree model and a Markov model 
was developed to compare the ICER of olanzapine and risperidone and determine the optimal 
alternative for schizophrenia treatment in Norway. The PANSS was used to measure 
effectiveness of the antipsychotics and costs were measured with a perspective of providers / 
funders of health and social care services in five years time frame. The Cochrane meta-analysis 
(1) and Norwegian cost analysis (2) provided the main source to operate the model.  
 
Results: The total five-year expected cost per schizophrenic patient for olanzapine was NOK 
1,878,072 and for risperidone NOK 1,943,868. The total expected PANSS reductions were 
112.60 and 111.55 for olanzapine and risperidone, respectively, thus olanzapine was a dominant 
alternative to risperidone. However, the results from the PSA using Monte Carlo simulation 
indicated that olanzapine and risperidone are not different in terms of cost-effectiveness within 
95% confidence interval. The ICE scatterplot demonstrated that the chance of olanzapine being 
an optimal alternative was 67.1% in the model. 
 
Discussion and conclusion: Considering all of the uncertainties surrounding the costs and 
effectiveness of the olanzapine and risperidone, the model could not conclude that olanzapine 
was more cost-effective than risperidone in Norway. For more precise results, further clinical 
trials are recommended to follow up patients who drop out of the study and evaluate relapse 
rates categorized into compliant and noncompliant patients distinctively. However, the model 
seemed capable to figure the overall total costs per schizophrenic patient treated with 
antipsychotic medications in Norway. In addition, the model can be used to provide a basic 






Schizophrenia is a serious mental disorder characterized by loss of contact with reality, 
hallucinations, delusions, abnormal thinking, and disrupted work and social functioning. This 
condition is a major public health problem throughout the world and known to be a major cause 
of disability. According to the study of 14 countries in 1999, active psychosis was ranked the 
third most disabling condition, after quadriplegia and dementia and before paraplegia and 
blindness (3). In spite of relatively low incidence rate, 0.1 to 0.4 per 1,000 population (4), 
schizophrenia has been one of the major contributors to the global burden of disease (5). In 
western countries, 1% of average gross domestic product was spent on the treatment, care and 
supports to people with schizophrenia diagnosis (6). In Norway, the direct and indirect costs 
associated with schizophrenic patients were calculated as NOK1 4 billion per year in 1995 and 
about NOK 7 billion per year were recalculated by reflecting inflation rates in 2002 i.e. 
schizophrenia was more costly than heart disease, cancer and rheumatic disease (7). 
 
Pharmacological therapy has been a main treatment for schizophrenic patients and olanzapine 
and risperidone are the most popular antipsychotics for non-refractory schizophrenia  (8). In 
Norway, according to Norwegian prescription database in 2007 (9), olanzapine and risperidone 
accounted about 55% of the total medication users for schizophrenia. As the most frequently 
prescribed antipsychotics for schizophrenia in Norway, there is an urgent need to critically 
examine olanzapine and risperidone based on evidence. This study was aimed at evaluating the 
incremental cost-effectiveness ratio of olanzapine versus risperidone in Norway by using a 
decision analytic model. The results will be of interest for those who are associated with 
schizophrenia; schizophrenic patients and their families, clinical practitioners and politicians in 
Norway. 
 
This study consists of six chapters. The second chapter explores general knowledge about 
schizophrenia and schizophrenia treatments and the third chapter proposes a current issue and 
                                                 
1 NOK refers to Norwegian krone. 
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objectives of this paper. In the fourth chapter, a decision analytic model and components of the 
model are described. In the fifth chapter, results produced by the model are presented. The 
results contain findings from a both discrete and stochastic model in order to demonstrate the 
consequences of including uncertainty into the estimations. Finally, the sixth chapter is to focus 
on weakness of the decision analytic model and deliberate feasibility of the findings being 






























The term schizophrenia from the Greek roots schizein (to split) and phren- (mind) was coined by 
a Swiss psychiatrist, Eugen Bleuler in 1908. Schizophrenia is a severe and disabling mental 
illness and the symptoms and severity can vary over individual with schizophrenia. 
 
2.1. Symptoms2 
The symptoms of schizophrenia fall into three groups; delusions and hallucinations, thought 
disorder and bizarre behavior and deficit or negative symptoms. Recently, however, dichotomy 
classification is also used; positive and negative symptoms. A person may have symptoms from 
one or all. 
 
Delusions are false beliefs that usually involve a misinterpretation of perceptions or experiences. 
For example, people with schizophrenia may experience persecutory delusions, believing that 
they are being tormented, followed, tricked, or spied on. They may have delusions of reference, 
believing that passages from books, newspapers, or song lyrics are directed specifically at them. 
They may have delusions of thought with drawl or thought insertion, believing that others can 
read their mind, that their thoughts are being transmitted to others, or that thoughts and impulses 
are being imposed on them by outside forces. Hallucinations of sounds, sight, smell, tastes, or 
touch may occur but auditory hallucinations and ideas of reference are the most frequently 
observed symptoms, found in about 70% of the patients (11). A person may hear voices 
commenting on his behavior, conversing with one another, or making critical and abusive 
comments.  
 
Thought disorder refers to disorganized thinking, which becomes apparent when speech is 
rambling, shifts from one topic to another and loses its goal-directed quality. Speech may be 
mildly disorganized or completely incoherent and incomprehensible. Bizarre behavior may take 
the form of childlike silliness, agitation, or inappropriate appearance, hygiene or conduct. 
                                                 
2 2.1 Symptoms mainly referred to the Merck manual of medical information (10). 
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Catatonic motor behavior is an extreme form of bizarre behavior in which a person may 
maintenance a rigid posture and resist efforts to be moved or, in contrast, display purposeless 
and unstimulated motor activity. However, the tendency to bizarre thinking and peculiar sensory 
experiences is spread across the population more widely than is usually acknowledged by 
clinicians (12). Therefore, symptom assessment may be a threshold issue and should always be 
seen within the context of the person’s overall emotional state and social functioning (13). 
 
Deficit or negative symptoms of schizophrenia include blunted affect, poverty of speech, 
anhedonia, and asociality. Blunted affect refers to a flattening of emotions. The person’s face 
may appear immobile; he makes poor eye contact and lacks emotional expressiveness. Events 
that would normally make a person laugh or cry produce no response. Poverty of speech refers 
to a diminishment of thoughts reflected in a decreased amount of speech. Answers to questions 
may be terse, one or two words, creating the impression of an inner emptiness. Anhedonia refers 
to a diminished capacity to experience pleasure; the person may take little interest in previous 
activities and spend more time in purposeless ones. Asociality refers to a lack of interest in 
relationships with other people. These negative symptoms are often associated with a general 
loss of motivation, sense of purpose, and goals. 
 
In the past 20 years, the distinction between the two broad categories of positive and negative 
symptoms gained widespread popularity have often been employed in economic evaluations 
(14). While positive symptoms refer symptoms of schizophrenia such as delusions, hallucination, 
thought disorder and bizarre behavior, negative symptoms refer symptoms of schizophrenia 
such as poverty of speech, lack of motivation, apathy and inability to express emotions.  
 
2.2. Diagnosis and prognosis 
In the absence of a biological marker, diagnosis of schizophrenia relies on examination of 
mental state, usually through a clinical interview, and observation of the patient’s behavior (13). 
As a standards used to diagnose schizophrenia, the International Statistical Classification of 
Diseases and Related Health Problems 10th Revision (ICD-10) is a global diagnostic tool 
(Appendix I). Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) is 
also a diagnostic manual published by the American Psychiatric Association (Appendix II). 
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Both tools are used for clinical practitioners in Norway. Although ICD-10 states seven sub-types 
of schizophrenia, careful standardized diagnostic assessment, while useful for research, may not 
be necessary in clinical practice and the diagnosis of schizophrenia does not carry enough 
information for treatment planning (13). 
 
Once a patient is diagnosed with schizophrenia, the patient may step forward following 
prognosis. In a longitudinal study, about one third of people with schizophrenia made a full 
recovery, about another one third showed improvement but not a full recovery, and a third 
remained ill in United States (15). In a recent community study, 62% showed overall 
improvement on a composite measure of symptomatic, clinical and functional outcomes at five 
years follow-up (16). Under specific factors patients with schizophrenia have bad prognosis. For 
example, the patients who gradually develop schizophrenia and live in the industrialized 
countries have bad prognosis. Substance abuse and a tendency to have social isolation are also 
the factors to cause bad prognosis (4). 
 
However, different dimensions of outcome such as social functioning, clinical symptoms and 
cognitive performance are often only weakly related, showing heterogeneity within individuals 
and leaving room for improvement in one area even though problems may persist in others (17). 
In addition, findings are not always comparable across studies because an exact definition of 
what constitutes recovery has not been widely accepted (18). 
 
2.3. Epidemiology and risk factors 
Lifetime risk of schizophrenia is about 1% (19) and the relatively similar results are found in 
different cultures (4). The incidence of schizophrenia is relatively low. In a WHO study, almost 
all of ten countries showed incidence rates per year for adult patients with schizophrenia within 
a quite narrow range of 0.1 and 0.4 per 1,000 populations (4). In Norway, the annual incidence 
is 0.07 to 0.15 per 1,000 and the prevalence of schizophrenia is about 3 to 5 per 1,000. 
Schizophrenia occurs equally in males and females although typically appears earlier with the 
peak ages of onset being 20 to 28 years for males and 26 to 32 years for females (20). Much 
rarer are examples of childhood onset (21) and late (middle age) or very late onset (old age) 
schizophrenia (22). Although schizophrenia is not in itself a fatal disease, death rates of people 
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with schizophrenia are at least twice as high as those in the general population (13). Suicide, 
particularly, has emerged as a growing matter of concern, since lifetime risk of suicide in 
schizophrenic disorders has been estimated at above 10%, which is about 12 times that of the 
general population (23). 
 
Risk factors for schizophrenia can, according to Cooper in 1978 (24), be grouped in three 
categories; sociodemographic characteristics, predisposing factors and precipitating factors. 
Within the Sociodemographic factor, the association between lower social class and 
schizophrenia in urban areas of developed countries is one of the most robust epidemiological 
findings (13). This is currently explained mainly by the selection-drift hypothesis, according to 
which individuals vulnerable to schizophrenia or with insidious onset of the disorder are either 
prevented from attaining higher class status or move progressively downward (25). However, it 
is possible that factors related to environmental conditions in lower class neighborhoods, such as 
occupational hazards, poor maternal and obstetric care or high psychosocial stressors, can play a 
role in some subgroups of people with schizophrenia. The complex social class related factors 
vary in occurrence of schizophrenia in different countries (13). In Norway, children of 
immigrates have high risk with schizophrenia and people living in urbane area have higher risk 
with schizophrenia than those living in inland (26). 
 
Among the predisposing factors, genetic ones are most important (13). Genetic contribution to 
liability for schizophrenia has been well estimated around 60% (27), although models of genetic 
transmission, predisposing genes and the link between genetic actors and the phenomenology of 
schizophrenia are far from being identified. Available data leave considerable room for 
environmental influences, as shown by concordance rates of less than 50% in monozygotic 
twins and lifetime risk of about 45% in children of two schizophrenic parents. Given the 
heterogeneous nature of schizophrenic disorders, it is also possible that both genetic and non-
genetic forms of the disorder exist (13). 
 
In the variety of interpersonal, social and cultural variables postulated as precipitating factors, 
family environment remains the best documented (13). A large body of research shows that 
family interaction patterns characterized by unclear or fragmented communication, negative 
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affective style, criticism, hostility and over involvement are strong predictors of relapse in 
schizophrenia, although evidence of their influence on onset is quite limited (28). There are also 
indications that other less defined aspects of family environment may exert protective effects on 
vulnerable individuals (29).  
 
2.4. Outcome measurements 
The Positive and Negative Syndrome Scale (PANSS) is a medical scale used for measuring 
symptom severity of patients with schizophrenia. The scale has 30 items, each of which can be 
defined on a seven-point scoring system varying from 1 - absent to 7 – extreme. So a lower 
score indicates less severity. The scale can be divided into three sub-scales for measuring the 
severity of general psychopathology, positive symptoms, PANSS-P, and negative symptoms, 
PANSS-N (30). Since the PANSS is a convenient method to perceive improvement on a 
patient’s mental status by treating with antipsychotics (30), it has widely used in the study of 
antipsychotic therapy. 
 
The Global Assessment of Functioning (GAF) Scale is a numeric scale (0 through 100) used by 
mental health clinicians and physicians to subjectively rate the social, occupational and 
psychological functioning of adults. The GAF Scale has a number of ranked sentences 
descriptive of psychiatric disturbance, associated with numerical ratings and it is used as a quick 
and simple measure of overall psychological disturbance (31). 
 
The Clinical Global Impression (CGI) Scale is a valid, reliable instrument to evaluate severity 
and treatment response in schizophrenia by thorough comparing with the PANSS and the GAF 
Scale (32). The CGI Scale is used to measure of symptom severity, treatment response and the 
efficacy of treatments on patients with mental disorders (33). Clinical trials with schizophrenia 
patients use the scale to assess both severity of illness and clinical improvement by comparing 
the conditions of the person standardized against other people with the same diagnosis (1). A 
seven-point scoring system is usually used with low scores showing decreased severity and/or 





The goal of treatment is to reduce severity of symptoms, prevent recurrences of symptomatic 
episodes and deterioration associated in functioning, and provide supports to allow functioning 
at the highest level possible (34). The pharmacological therapy has become a main treatment for 
schizophrenia since treatment was revolutionized in the mid 1950s with development of 
antipsychotic medications (35). Recently, the psycho educational therapy such as family therapy 
and cognitive therapy appeared as alternatives (36). However, those new alternative treatments 
are not practiced as standard treatments in Norway due to lack of sufficient documented studies 
over patients with schizophrenia (37). 
 
The pharmacological therapy centred on the use of dopamine receptor blockers, such as 
chlorpromazine and haloperidol. Those antipsychotic medications are known as typical 
antipsychotics3. These agents had been shown to be more effective than placebo in controlling 
the positive symptoms of schizophrenia (38) and in moderating acute episodes of schizophrenia 
in clinical trials (39). However, although representing a major stepped forward in the treatment 
of schizophrenia when initially introduced, the overall impact of typical antipsychotic 
medications was disappointing (40). About 30% of individuals complying with typical 
antipsychotics regimens derived little or non benefit in terms of symptom control or reduction, 
while another 30% gained only partial relief (41).  
 
In addition, typical antipsychotics appeared to involve high risk of side-effects (42). 
Chlorpromazine seemed to cause sedation, acute movement disorders, parkinsonism, 
hypotension and weight gain (38) and dystonia, akathisia and parkinsonism were found in 
patients with haloperidol (39). Besides, extrapyramidal symptoms (EPSs) were the most 
troublesome (40). EPSs refer to movement disorders that occur when there is a disruption of the 
brain's extrapyramidal system4. As a term, EPSs include following symptoms; akinesia 
(inability to initiate movement), akathisia (inability to remain motionless), dystonia (muscular 
spasms of neck - torticollis, eyes - oculogyric crisis, tongue, or jaw; more frequent in children) 
                                                 
3 The term typical antipsychotics has following synonyms; conventional antipsychotics, first generation 
antipsychotics, classical neuroleptics and major tranquilizers. 
4 In human anatomy, the extrapyramidal system is a neural network located in the brain that is a part of the motor 
system involved in the coordination of movement 
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and tardive dyskinesia (involuntary, irregular muscle movements, usually in the face). Long-
term use of typical antipsychotics drugs was associated with a high risk of debilitating 
neurological side-effects, notably tardive dyskinesia, as well as shorter-term effects such as 
akathisia and dystonia (40).  
 
In response to the problems, the pharmaceutical industry had developed atypical antipsychotics5. 
Atypical antipsychotics are now widely used in the treatment of schizophrenia and, with the 
introduction of additional atypical agents. The negative symptoms responded better to atypical 
antipsychotics (21) and in general side-effects appeared less severely to atypical antipsychotics 
than conventional (40). As a results, recent guidelines in treating schizophrenia recommend the 
use of atypical antipsychotic medications (43,44). 
 
2.6. Olanzapine and risperidone 
Up to recently, the antipsychotic medications are the mainstay of treatment for schizophrenia 
and there is a trend towards greater use of new antipsychotics, especially olanzapine and 
risperidone (1). Because of their greater clinical efficacy and relatively benign adverse effects, 
olanzapine and risperidone became the most frequently prescribed antipsychotics (8). In UK, 
olanzapine and risperidone accounted for nearly half of all the antipsychotics prescribed and 
more than 90% of the atypical antipsychotics prescribed (45). The increase of using the 
antipsychotics is likely to be mirrored in low and middle income countries, where approximately 
80% of people suffering from schizophrenia reside (46).  
 
In United States, only clozapine, risperidone, olanzapine, and quetiapine carried FDA-approved 
labeling for use in the treatment of schizophrenia in 2002. At usual dosages, olanzapine and 
risperidone appeared with greater efficacy and a lower rate of adverse events than conventional 
antipsychotics (47-51). Although quetiapine was found to be superior to placebo, it did not 
provide any clinical advantage over conventional agents, such as chlorpromazine and 
haloperidol (52-54). Clozapine was also not considered a first-line agent for treating 
schizophrenia because of its propensity to cause agranulocytosis (55). Although olanzapine and 
                                                 
5 The term atypical antipsychotics is a synonym of second generation antipsychotics and inconventional 
antipsychotics. 
 15
risperidone were approximately 10 times more expensive than conventional antipsychotics, 
researchers suggested that if they would reduce a person’s need for inpatient services, their use 

































As seen in chapter 2, olanzapine and risperidone became so-called novel antipsychotic 
medication. However, although the whole sale price of olanzapine is double as that of 
risperidone (58), the number of users with olanzapine is almost double to risperidone, as there 
are total 15,637 olanzapine users and 7,891 risperidone users in Norway in 2007 (9). A number 
of economic evaluations have been performed to compare olanzapine and risperidone. 
Nevertheless, the answer is still debated.  
 
3.1. Literature review 
Following electronic database were used to search economic evaluations of olanzapine and/or 
risperidone; Pubmed, Medline, Embase, Cochrane Library, PsychInfo and Google Scholar. 
 
Olanzapine and risperidone are known as both safe and effective for the management of non-
refractory patients but degree of efficacy on negative symptoms and aspects of side-effects 
appeared differently (51). In clinical trials, risperidone seemed associated with a greater 
frequency of orthostasis, corrected QT-interval prolongation, sexual dysfunction, and 
hyperprolactinemia (59,60). In an economic evaluation of antipsychotics for schizophrenia, 
risperidone caused EPSs significantly less frequently than with conventional agents but probably 
more frequently than other atypical antipsychotics at higher dosages (61). Also, more tardive 
dyskinesia cases were reported in taking risperidone than other atypical antipsychotics (62-65). 
In a study of adverse effects and costs, however, the author argued that because of its broad 
receptor-binding profile, olanzapine was linked to a higher frequency of anticholinergic effects 
than risperidone and weight gain occurred more often with olanzapine (59). In a clinical efficacy 
meta-analysis, it was argued that risperidone-treated patients had a lower risk of withdrawal and 
in terms of safety, risperidone-treated patients required less anti-EPS medication than patients 
treated with typical antipsychotic medications and lastly they concluded that risperidone might 
show clearer benefits in terms of efficacy than olanzapine (66).  
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Inconsistency of findings reported by various forms of comparing olanzapine and risperidone 
was found through literature review. A broad systematic review of atypical antipsychotic 
medications concluded that the evidence for the effectiveness of the new atypical antipsychotic 
medications was, in general, of poor quality, based on short-term trials and difficult to generalise 
to the whole population with schizophrenia (40). In addition, the tendency to favor 
antipsychotics for sponsorship pharmaceuticals had worsened the situation. According to the 
overview of clinical trials of olanzapine and risperidone, 33 of the 42 reports were sponsored by 
a pharmaceutical company and 90% of the studies reported that overall outcomes were in favor 
of the sponsor’s drug (67). 
 
3.2. Economic evaluation 
An economic evaluation is the comparative analysis of alternative courses of action in terms of 
both their costs and consequences (68). The basic tasks of the economic evaluation consist of 
identifying, measuring and valuing costs and consequences the alternatives being considered in 
an incremental analysis, i.e. that the difference costs is compared with the difference in 
consequences (68). As a result, an economic evaluation enables patients and clinical 
practitioners to choose an optimal alternative, programme administrators to optimize resources 
allocation and policy makers to make informed decisions and to maximize utility to a society.  
 
3.2.1. CEA, CUA and CBA6
A full economic evaluation often has three approaches; Cost-Effectiveness Analysis (CEA), 
Cost-Utility Analysis (CUA) and Cost-Benefit Analysis (CBA). First, in CEA, the incremental 
cost of a programme from a particular viewpoint is compared to the incremental health effects of 
the programme, where the health effects are measured in natural units related to the objectives of 
the programme. CEA are of use in situations where a decision maker, operating with a given 
budget is considering a limited rage of options within a given field. Second, in CUA, the 
incremental cost of a programme from a particular viewpoint is compared to the incremental 
health improvement attributable to the programme, where the health improvement is measured 
in quality-adjusted life-year (QALYs) gained or disability adjusted life-years (DALYs) gained. 
In contrast to CEA, CUA outcomes are generic as opposed to programme specific and 
                                                 
6 3.2.1 CEA, CUA and CBA mainly referred to Methods for the economic evaluation of health care (68). 
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incorporate the notion of value. Last, CBA requires programme consequences to be valued in 
monetary units, thus enabling the analyst to make a direct comparison of the programme’s 
incremental cost with its incremental consequences in commensurate units of measurement. 
Because CBA converts all costs and benefits to money it is not restricted to comparing 
programmes within health care but can be used to inform resource allocation decisions both 
within and between sectors of the economy. Due to limit of available data, however, CEA with a 
decision analytic model was conducted. 
 
3.2.2. Decision making in CEA 
An optimal alternative is determined primarily upon results of comparing the incremental cost 
and the incremental effectiveness of alternatives. If an intervention is both less costly and more 
effective than a comparator, the intervention is dominant to or dominating the comparator. In  
 
Figure 1. Dominant and dominated alternative in a cost-effect plane Adapted from Black (1990)
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opposite, if an intervention both costs more and is less effective than a comparator, the 
intervention is dominated to the comparator. When effectiveness is plotted on the X axis, an 
option is dominated if it lies above and to the left of another alternative. The option below and to 
the right is referred to as dominant, or dominating (Figure 1). 
 
If an intervention both costs more and is more effective or an intervention both costs less and is 
less effective than a comparator, external standards are needed. As one of the external standards 









01                                                                                                                  [1] 
 
ICER is defined as the ratio of the difference between costs of an intervention (C1) and initial 
costs (C0) to the difference between effects of the intervention (E1) and initial effects (E0). Using 
ICER, an optimal alternative is defined where the ICER is less than a threshold ratio or the 
minimum ICER among the ICERs of alternatives.  
 
Although the ICER remains the most popular method of presenting the result of CEA, it does 
have draw backs. For example, the ratio gives no idea of the size or scale of the treatments or 
programmes being considered (68). So Net benefit was proposed as an alternative summary 
measure of the value for money of health care programmes (69). The net benefit approach 
employs a simple rearrangement of the cost effectiveness decision rule which is that an 
intervention is deemed cost effective if ICER is less than a threshold ratio. The net monetary 
benefit (NMB) is defined as 
 
0>Δ−Δ×= CERNMB T                                                                                                               [2] 
 
Where ΔE is the increase in effectiveness, RT is the amount the decision maker is willing to pay 
per unit of increased effectiveness and ΔC is the change in costs. Willingness-to- pay (WTP) is 
the maximum monetary amount that an individual would pay to obtain a good. Consequently, 
RT*ΔE has to be greater than ΔC for NMB to be positive.  
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3.2.3. Sensitivity analysis 
In situations where no good clinical evidence exists, the cost-effectiveness analyst may proceed 
by making assumptions about the clinical evidence and undertaking sensitivity analysis of the 
economic results to different assumptions (68). In situations where heterogeneity in study 
population characteristics might have impacts on varying effects or costs, sensitivity analysis is 
also preferable. 
 
To investigate the robustness of a study with a form of mathematical modelling, when the study 
contains potential to wave the results by parameters associated with uncertainty, one-way 
sensitivity analysis can demonstrate changes of results by varying an uncertain parameter within 
a range of variables. Multiple-way sensitivity analysis examines simultaneous changes of results 
by varying more than two uncertain parameters. A tornado diagram is a set of one-way 
sensitivity analyses brings together in a single graph.  Each expected value generated by varying 
uncertainty related parameters is displayed on a horizontal axis in rank order by size, so the 
parameter with the largest potential impact on results can be seen in the diagram.  
 
However, those sensitivity analyses, called deterministic sensitivity analysis7 have following 
drawbacks especially in using decision analytic modelling. Drummond (68) argued that first, 
with standards (deterministic) sensitivity analysis it is only practical to vary a small number of 
parameters simultaneously but most models include more input parameters than limits one or 
two. Second, when input parameters in the model are correlated, the correlation is not handled. 
Third, there is no suitable summary measure of the implications of the uncertainty. In face of the 
limitations of standard sensitivity analyses, probabilistic sensitivity analysis (PSA) has been 
discussed (70). In PSA, input parameters are defined in as probability distributions to reflect the 
parameters’ full uncertainty. By using Monte Carlo simulation propagating input parameters 
within randomly sampled from the probability distributions, the end result is computed as a 
large number (for example, 10,000) of sets of expected costs and effects that combined 
parameter uncertainty in the model. An advantage of the PSA using Monte Carlo simulation is 
that uncertainty associated with all of the parameters can be incorporated in an analysis. 
Sampling parameter values from probability distributions (rather than from a deterministic range, 
                                                 
7 Deterministic sensitivity analysis is named after that the set of range with parameters is deterministic. 
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upper and lower bounds) places greater weight on likely combinations of parameter values, and 
simulation results quantify the total impact of uncertainty on the model within confidence level, 
which can be placed in the analysis results. 
 
As one of outputs of the PSA using Monte Carlo Simulation, the Incremental Cost-Effectiveness 
(ICE) scatterplot is used for decision making. The ICE scatterplot uses a form of the standard 
Cost-Effect plane to plot points for each iteration in the simulation output. The ICE scatterplot 
includes a single set of points representing pairs of the incremental cost and effectiveness values 
from the simulation results, based on a comparator relative to a baseline alternative. The WTP 
line in the graph intersects points having the specified ICER value, and the region below the line 
includes cost-effective points. For each plotted result, the comparator will be cost-effective 





1 Comparator dominates the baseline 
2 
Comparator is more costly and effective, 
and its ICER is less than or equal to the 
WTP, so it is cost-effective 
3 
Baseline is more costly and effective, but 
its ICER is greater than the WTP, so the 
comparator is optimal 
4 
Comparator is more costly and effective, 
but its ICER is greater than the WTP, so 
the baseline is optimal 
5 
Baseline is more costly and effective, and 
its ICER is less than or equal to the WTP, 
so it is optimal 
6 Baseline dominates the comparator 
Indiff Indifference, incremental cost and effect close to zero  
* Source: TreeAge Pro 2009 user’s manual 
Figure 2. The ICE scatterplot and interpretation 
 22
3.3. Research question 
This study was aimed at comparing the ICER of olanzapine and risperidone and determining 
which alternative is a more cost-effective antipsychotic medication for schizophrenia in Norway. 
The perspective of the analysis was constrained to providers of health and social care services. 
While this did not extend to a full societal perspective, it did include those perspectives where 
the use of atypical antipsychotics is likely to have a major impact. To be consistent with the 
population targeted by current clinical guidelines (71), the analysis was restricted to a 
consideration of the likely costs and consequences for patients with schizophrenia in age range 
from 16 to 65 in Norway. On a base of clinical guidelines and prior decision analytic models, a 
decision analytic model was developed to compare the expected costs and consequences of 
schizophrenic patients with the antipsychotic medications and estimate the range of uncertainty 
surrounding the results. One-way sensitivity analysis, two-way sensitivity analysis and the PSA 
were performed to examine robustness of findings in association with uncertainty. 
 
Table 1. Core issues in the economic evaluation 
Core issues   
Comparators Olanzapine 10mg and risperidone 4 mg 
Objective Comparing ICER of the antipsychotics 
Population Diagnosis: schizophrenia (DSM-IV), age 18-65 in Norway 
Perspective Providers/funders of health and social care services 
Approach CEA with a decision analytic model combined of decision tree model and Markov model 
Time frame Five years 
Outcome measures The PANSS score 
Main source of  
the effectiveness  Meta-analysis (Cochrane 2005) 
Unit costs Medication market prices, clinician’s fee schedules, empirical cost data in Norway 
Cost currency Norwegian Krone (NOK) in 2008 
Discount rate (%) 4% 





When extensive prospective health economic data are limited and/or based on varying 
assumptions, economic decision model are frequently used to identify cost effective solutions 
(72). This type of method is relatively rapid to estimate the economic impact of antipsychotic 
medications and provides the flexibility to compare different antipsychotics, to incorporate 
different treatment patterns, structures and duration (73). Although in clinical medicine and 
epidemiology the randomized, double-masked, prospective trial may be considered essential, 
social and economic analysts have long used modelling to simulate real-life usage. Also, models 
allow individual variables to be altered in a manner that is impossible in prospective trials (74).  
 
4.1. A decision analytic model 
The decision analytic model examined costs and health consequences of treatment alternatives; 
olanzapine 10mg and risperidone 4mg over five years in Norway. The model was based on 
Norwegian electronic physician guidebook (34), a review of pharmacoeconomic modeling on 
schizophrenia (72) and decision analytic models in prior studies (75-77).  
 
Tree Age Pro Healthcare Module 2008 program was used to calculate ICER of the comparators 
and operate the PSA, one-way sensitivity analysis and two-way sensitivity analysis. In the 
model, both pathways of olanzapine and risperidone are equally given but probabilities for each 
of the pathways are different and that, along the difference in the resource use, have impact on 
results. There are four main node types: A decision node indicates a choice facing the decision 
maker. A chance node is an event which has multiple possible outcomes and is not under the 
decision maker’s control. A terminal node denotes the endpoint of a scenario. A Markov node 
indicates the beginning spot of Markov process8. 
 
                                                 
8 A Markov process is a mathematical model for the random evolution of a memoryless system, that is, one for 
which the likelihood of a given future state, at any given moment, depends only on its present state and not on any 
past states. 
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4.2. Model description 
The model consists of two distinct stages to reflect the treatment process for schizophrenia 
patients in Norway. First, the acute stage reflects the initial 16 weeks period of acute treatment 
in which the treatment is primarily aimed at reducing the current acute symptoms and stabilizing 
the patients. During the initial 16 weeks, a clinician evaluates responds of the initial treatment 
and the switched antipsychotics. Second, the maintenance stage (from the 16th week to 5th year) 
is a stage of prolonged longer term preventative treatment aimed at preventing acute relapses. 
Figure 3 illustrates a simplified structure of the model.  
 
 
Figure 3. A simplified structure of the decision analytic model 
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4.2.1. The acute stage (from the baseline to 8th or 16th week) 
At the beginning, a clinician makes a decision whether to treat patients with schizophrenia 
diagnosis with olanzapine 10mg or risperidone 4mg. Doses of the antipsychotics were based on 
both HTA guideline for cost-effectiveness analysis for antipsychotics9 (40) and clinical trials 
providing the effectiveness data in the model (71,78). Some of the patients do not complete the 
treatments and leave study early due to, for example, adverse effects and lack of medication’s 
efficacy (noted as drop out in the model). It is common in schizophrenia pathology that patients 
often drop out of health care systems and reappear at hospitals later (72). The others continue 
the treatment. In the 8th week, the clinician evaluates the patients’ mental state and responds to 
the initial treatment. The patients who have more than 40% reduction from the baseline PANSS 
are classified as adequate respond. The patients who have between 20% and 40% reduction 
from the baseline PANSS score are classified as mild respond. The patients with adequate 
respond or mild respond continue the initial treatment and enter the maintenance stage unless 
the adverse events are intolerable. If the adverse events are intolerable or the reduction in the 
baseline PANSS score is less than 20% (inadequate respond), the clinician switches the initial 
(1st line) treatment to the second (2nd line) treatment, i.e. olanzapine to risperidone or visa versa. 
It was assumed that prior use of taking an antipsychotic did not influence the effectiveness of 
the use of the other antipsychotics. The switching strategy is to reflect clinicians’ practice 
dealing with adverse events. When adverse events occur to schizophrenic patients, according to 
a Spanish non-interventional cross-sectional study (79), about half of the patients continued the 
treatment with no action, 30% of them used medication for handling the adverse events and only 
5 % switched the initial antipsychotics (80).  
 
Some of the patients drop out of the second treatment between the 8th and 16th week. At 16th 
week, the clinician evaluates the patients’ mental state and the respond to the second treatment. 
Those who have either adequate respond or mild respond continue the second treatment and 
enter the maintenance stage unless the adverse events are intolerable. If the adverse events are 
intolerable or the responds to the second treatment is inadequate, the clinician switches to 
treatment with clozapine (3rd line). 
                                                 
9 The recommended dose of antipsychotics for schizophrenia: olanzapine; 5–20 mg daily, risperidone; 3–6 mg daily, 
and clozapine; 150–450 mg daily (40). 
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4.2.2. The maintenance stage (from 16th week to 5th year) 
The maintenance stage was developed in the form of Markov model firstly to describe acute 
relapse and stabilizing process and secondly to track the long term treatment experience of 
patients and the associated health care resource use and costs. The pattern of repeated acute 
relapses of symptoms is typically seen in the majority of patients with diagnosed schizophrenia 
(81) and the Markov model is suited to modelling repeated events or the progression of chronic 
diseases such as schizophrenia (72). In the maintenance stage, patients are assumed to remain on 
a stable condition with controlled symptoms unless they experience an acute relapse of 
symptoms in a three months cycle which repeats 20 times to complete five years time frame. 
According to methodology study in economics evaluation (82), an informative prediction model 
has five years time frame, preferably with the ability to project throughout a patient’s lifetime. 
 
In the maintenance stage, the patients are assumed to continue the initial or second treatment 
that they respond on adequately or mildly without intolerable adverse events during the acute 
stage. In practice, however, a certain percentage of the patients are always noncompliant, which 
influences the relapse rate (83). Acute relapse among noncompliant patients is more frequent, 
disruptive, and severe (84). In the beginning of the maintenance stage, acute relapse occurs at a 
lower rate for compliant patents than for noncompliant patients. Patients without acute relapse 
remain in the stable maintenance stage until the end of the cycles. Once an acute relapse occurs, 
the patients move into one of two modalities of health care service depending on the setting of 
their treatment; hospitalized care or community based care (CBC). During the acute relapse, 
some of the patients attempt suicide. Some of those with a suicide attempt survive and the rest 
ends in death. After completing their treatment, the patients return to the stable condition with 
controlled symptoms and go through this process in another cycle. In the maintenance stage, it is 
assumed that suicide is the only cause of death and the others remain in the repeating cycles. 
  
In the decision analytic model, following assumptions were additionally made. In the maintain 
stage, it is assumed that the PANSS score decline with 5% every cycle in the first year in order 
to reflect that the symptoms relieve with time passing. In a long term clinical trial of olanzapine 
and risperidone, it was reported that the proportion of patients with either adequate respond or 
mild respond increased with 50% from the 8th until the 28th weeks (1). However, since the aim 
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of long term treatment is avoidance of relapse, not reducing the acute symptoms, PANSS score 
reduction was not considered from the second year in the model. Therefore, only the acute stage 
and the first year in the maintain stage produced accessible data for performing cost 
effectiveness analysis. The utility of the maintenance stage from the second to fifth year was 
limited as supplement to calculate the expected value of the costs in five years. Another 
additional assumption was that the compliance rate was applied only for the first year in the 
maintenance stage due to lack of available data.  
 
Table 2. Definition of model elements 
Model element Definition 
Acute stage  Initial treatment period targeted at reducing the acute symptoms of a schizophrenic episode 
 Drop out Incomplete treatment and leaving study early  
 Adequate respond Reduction from the baseline in PANSS > 40%  
 Mild respond Reduction from the baseline in PANSS >20%  and < 40% 
 Inadequate respond Reduction from the baseline in PANSS < 20% 
 Intolerable adverse events A condition that a patient has to stop taking the antipsychotic due to serious side effects 
 The initial treatment 1st line treatment., an antipsychotic that a patient is initially prescribed for 
 The second treatment 2
nd line treatment, the other alternative that a patient is switched from 1st line 
treatment due to intolerable adverse events or inadequate respond. 
Maintenance stage The prolonged treatment, after acute symptoms have been reduced, targeted at delaying or avoiding any repeat acute episodes 
 Non compliance Refusal to adhere to a treatment regime which have adequate or mild symptom control 
 Acute relapse A new episode of schizophrenic symptoms that require clinical management, experienced after a period of stabilizing 
 Hospitalized care Acute care set in the context of inpatient care in a hospital 
 Community based care Acute care set in the context of a community service 
 Suicide attempt Suicide attempt during an acute relapse episode in the maintenance stage 
 Death Death due to suicide attempt 
 
 28
Below is summary of assumptions in the model. 
 The initial treatment does not influence on effectiveness of the second treatment. 
 In the maintenance stage, patients continue the initial or second treatment which they have the adequate 
or mild respond without intolerable adverse events during their acute stage. 
 In the maintenance, stage patients remain on a stable condition with controlled symptoms unless they 
experience an acute relapse of symptoms. 
 One cycle has the 3 months time perspective. 
 Suicide death is only way out of the cycle and the rest of them stay in the repeating cycle in the 
maintenance stage. 
 5% of PANSS score fall down to all of the patients in the 1st to 4th 3 months-cycle in the maintenance 
stage. 
 The maintenance stage begins with acute relapse or non acute relapse from the 5th cycle. 
 
4.3. Clinical effectiveness and probabilities 
Although it is primarily a clinical issue, the availability of good quality data on the effectiveness 
of the treatments being assessed is crucial to the CEA. In fact, CEAs are more often criticized 
for the quality of the effectiveness evidence on which they are based, rather than for the 
subsequent economics (68). To search quality data on the effectiveness of olanzapine and 
risperidone, I used following electronic databases; Pubmed, Medline, Embase, Cochrane Library, 
PsychInfo, Cinahl, Social Services Abstracts, Sociological Abstracts, Eric, International 
Bibliography of the Social Sciences, Social Sciences Citation Index, Social Care Online, C2-
SPECTR, SveMed, BiblioMap, Bibsys and Google Scholar. 
 
A meta-analysis in a systematic review; Risperidone versus olanzapine for schizophrenia (1) 
provided main effectiveness and probability data used in the model. The meta-analysis included 
16 studies after the inclusion criteria reviewing 52 studies and excluded studies with inadequate 
level of allocation concealment. This was one of strengths of the meta-analysis as Drummond 
argued that probably the most important aspect is the random allocation of patients to treatment 
groups for methodological features of a well-designed study to assess effectiveness (68). 
Besides, another advantage of using the meta-analysis is of comprehensiveness in the 
effectiveness evidence. Through investigating a wide extent of citations of the studies, the 
systematic review could handle the issue that selective use of clinical data in an economic 
evaluation results in a more favourable cost effectiveness assessment than would have been the 
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case if all the available data are used (85). Appendix III summarizes studies used as source 
providing the effectiveness and probability data on olanzapine and risperidone in the model. 
 
In the acute stage, the respond to the initial and second treatment referred to the short term 
(8weeks) effectiveness data. The decision analytic model did not refer to the long term 
(28weeks) effectiveness data but used them as the base of notion that 5% reduction in PANSS 
score takes a place in each cycle in the first year. To input actual reduced PANSS score as the 
effects of olanzapine and risperidone in stead of reduced percentage into the decision analytic 
model, the following procedure was needed. In the short term study of olanzapine and 
risperidone, the mean baseline PANSS score of the population was 80.9 (SD=13.0, the mean 
baseline PANSS score of the olanzapine group=81.2, that of the risperidone group=80.7) (71). 
The mean PANSS reduction from the base line of the adequate respond group was assumed 50% 
and those of the mild respond and inadequate group were 30% and 10%, respectively. Therefore, 
the mean PANSS reduced score of the adequate respond group was 40.5(=80.9*0.5), the mean 
PANSS reduced score of the mild respond group was 24.3(=80.9*0.3), the mean PANSS 
reduced score of the inadequate group was 8.1(=80.9*0.1) and lastly, the mean PANSS reduced 
score of 5% reduction was 4.5(=80.9*0.05).  
 
Table 3. Clinical data on response and intolerable adverse events to the antipsychotics 
 Olanzapine Risperidone Reference 
 n / N (%) n / N (%)  
Adequate respond, >40% reduction from the 
baseline in the PANSS/ 8weeks 50/277 (0.181) 62/275 (0.225) (71), (78) 
Mild respond, > 20%< 40% reduction from 
the baseline in the PANSS/ 8weeks 69/277 (0.249) 55/275 (0.200) (71), (78) 
Inadequate respond, < 20% reduction from 
the baseline in the PANSS/ 8weeks 158/277 (0.570) 158/275 (0.575) (71), (78) 
Adequate respond, >40% reduction from the 
baseline in the PANSS/ 28weeks 70/172 (0,407) 63/167 (0,377) (51) 
Mild respond, > 20%< 40% reduction from 
the baseline in the PANSS/ 28weeks 41/172 (0,238) 60/167 (0,359) (51) 
Inadequate respond, < 20% reduction from 
the baseline in the PANSS/ 28weeks 31/172 (0,355) 44/167 (0,263) (51)) 
* Source: a systematic review; risperidone versus olanzapine for schizophrenia (1) 
 
Most of the probabilities were based on the meta-analysis (1), but some probabilities referred to 
other studies. Following three, the probability of acute relapse to noncompliant patients, the 
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probability of acute relapse from the second year and the probability of hospitalized care 
referred to estimates or expert’s opinions10 from the prior economic evaluations using an 
analytic model (75-77).  
 
Table 4. Probabilities used in the model 
Probability Olanzapine Risperidone Reference 
Acute stage (8 or 16weeks)    
 Drop out 0.189 0.221 (86), (71), (87), (78), (88), (89), (51) 
 Continue #1 # - 
 Adequate respond 0.181 0.225 (71), (78) 
 Mild respond # # - 
 Inadequate respond 0.570 0.575 (71), (78) 
 Intolerable AE 0.095 0.097 (90) 
 Tolerable AE # # - 
Maintenance stage    
 Noncompliance2, 3 0.141 0.115 (90), (91), (92), (51) 
 Compliance # # - 
 Acute relapse, compliance 0.098 0.365 Estimated (Appendix IV) 
 Non acute relapse, compliance # # - 
 Acute relapse, noncompliance 0.750 0.750 (77) 
 Non acute relapse, noncompliance # # - 
 Acute relapse (from 2nd year ) 0.094 0.094 (76) 
 Non acute relapse (from 2nd year) # # - 
 Hospitalized care 0.700 0.700 (75) 
 Community based care # # - 
 Suicide attempt 0.013 0.018 (93), (90), (71), (92), (51) 
 No suicide attempt # # - 
 Suicide death 0.397 0.395 (71), (78), (89) 
 Suicide survival # # - 
* Main source: A systematic review; Risperidone versus olanzapine for schizophrenia (1) 
 
1. The sharp note (#) indicates the probability which makes sum of branches one at the chance node. For example, 
the sum of the probability of drop out and continue has to be one so the probability of continue, olanzapine is 
0.801(=1-0.189). 
2. As a surrogate measure of noncompliance, leaving the study early due to adverse events was used.  
3. Noncompliance and compliance rate were applied only until the 4th cycle. 
                                                 
10 The expert team consisted of a published health economist in the mental health sector and three clinical 
psychiatrists/psychotherapists to provide clinical and health economic experience of treating schizophrenia in 
Germany (75). 
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The probabilities of acute relapse for complaint patients with olanzapine and risperidone were 
estimated on the base of relapse/hospitalization data (94) and an explanatory estimating process, 
illustrated in Appendix IV. All of the probabilities used in the model are summarized in Table 4.  
  
4.4. Health care resources 
Patients with schizophrenia are expected to consume different levels of health care resource 
during the treatment. Since the healthcare resource consumed in this study are constrained to the 
perspective of the providers in the health and social care services, the health care sectors and the 
other sectors in schizophrenia treatment were identified, measured and valued. Resources in the 
health care sector consist of factors such as drugs, equipment, hospitalization, physician visits 
and so on. Resources consumed in other sectors are likely to be, for example, use of homemaker 
services, nursing home care or voluntary services (68). The patient and family resources11 and 
productivity losses were not included. 
 
In this study, the amount of each service unit cost referred to the costs of services for 
schizophrenic patients in Norway (2). In 1999, Rund and Ruud estimated that the total direct 
costs of mental health services for schizophrenic patients were NOK 1,158 million per year 
(US$ 164 million). The estimation was based on gross expense for the institutions including all 
overhead costs12 in duration of 4weeks in 1994. All treatment units serving 6 catchment areas 
with a total population of 425,000 (9.9% of the population of Norway) were considered to be 
representative of the country as a whole (2).  
 
4.4.1. Drug cost 
Drug costs referred to the price list of medication sold in Norway (58). In the model, patients 
continue to use olanzapine 10mg or risperidone 4mg daily (or clozapine 300 mg as 3rd line 
treatment). As one common type of medications to handle EPSs in Norway, Biperiden 2mg is 
taken twice a day for patients with EPSs in the model. The costs of taking Biperiden were 
                                                 
11 The patient and family resources could consist of out of pocket expenses in traveling to hospital, various co-
payments and expenditure in the home. The time could either be from leisure activities or work time, which would 
affect its valuation (68). 
12 All overhead costs were defined as shared costs for administration, technical services and other services in the 
Study (2) 
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related to the probabilities of EPSs occurring in the model. The probabilities of EPSs occurring 
seemed lower for long-term use than for short-term use. 
 
Table 5. The probability of EPSs occurring 
Period olanzapine risperidone Reference 
by 8 weeks 0.35 0.48 (51), (95) 
by 3 to 12 month 0.19 0.33 (51), (95) 
over 52 weeks 0.08 0.11 (90), (92) 
* Source: a systematic review; risperidone versus olanzapine for schizophrenia (1) 
 
4.4.2. Community based care cost 
Since schizophrenia is a chronic condition and relapse is common, schizophrenic patients are 
expected to consume community based care (CBC) on a regular basis even if the symptoms are 
stabilized. Considering the nature of schizophrenia, CBC was divided in three ways in the model.  
 
Table 6. Total costs for CBC in 3 months (NOK in 2008) 
  Number of visit Cost per visit Proportion of use NOK 
CBC stable maintenance   
 Psychiatrist + psychologist 6 visits + 1 GP    760 0.5 2,425
 GP 6 visits    289 0.2 347
 Out-patient 6 visits 1,800 0.3 3,240
 Total   1.0 6,011
CBC non-hospital relapse management  
 Psychiatrist + psychologist 18 visits    760 0.5 6,840
 GP 18 visits    289 0.2 1,040
 Out-patient 18 visits 1,800 0.3 9,720
 Total   1.0 17,600
CBC post-hospital relapse management   
 Psychiatrist + psychologist 18 visits    760 0.65 8,892
 GP 18 visits    289 0.10 520
 Out-patient 18 visits 1,800 0.25 8,100
 Total   1.00 17,512
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In the maintenance stage, patients consume CBC on a regular basis unless they experience acute 
relapses (CBC stable maintenance). Some of the patients with acute relapse increase CBC for 
the complete duration of their acute relapse (CBC non-hospital relapse management). 
Alternatively, rest of the patients with acute relapse move into a hospital and consume CBC for 
the remainder of their acute relapse after being discharged (CBC post-hospital relapse 
management). The cost per visit referred to fee schedules for GP, psychiatrist, psychologist and 
out patient clinic in Norway (97). The number of clinical services visit and the proportion of use 
referred to experts’ opinion (75).  
 
4.4.3. Residential care cost 
In the model, the residential care consists of home, partial sheltered accommodation and full 
sheltered accommodation. Schizophrenic patients are expected to stay in one of those residential 
modalities depending on severity of the symptoms. The residential care cost occurs concurrently 
along with CBC services and the residential care cost does not count the days of hospitalization 
when patients with acute relapse are hospitalized. The partial sheltered accommodation cost per 
day referred to day unit care cost and the full sheltered accommodation cost per day referred to 
psychiatric nursing home cost from empirical cost data in Norway (2). The cost values were 
converted into 2008 by Customer Price Index (CPI)13. The proportion of use referred to experts’ 
opinion (75). 
 
Table 7. Total costs for residential care in 3 months (NOK in 2008) 
  Cost per day Cost for 3months Proportion of use  
Home 0 0 0.8 0
Sheltered accommondation (partial) 67 6,020 0.1 602
Sheltered accommondation (full) 1,584 142,590 0.1 14,259
Total  - - 1.0 14,861
 
 
                                                 
13 Web-based Inflation calculator: http://www.ssb.no/vis/kpi/kpiregn.html, authorized by Statistics Norway 
(Statistisk sentralbyrå) 
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4.4.4. Hospitalized care cost 
During 8 weeks of the acute stage, the patients are hospitalized for 4 weeks. The length of 
hospitalization in the acute stage was based on a short-term clinical trial for schizophrenia (71). 
The 2nd line respondents are assumed to be hospitalized for another 4 weeks because the 
clinician needs another period of evaluation. The hospitalized care cost per day refers to the total 
cost of acute wards, sub acute wards and long term wards for schizophrenic patients in Norway 
(2) and the cost values reflected inflation rates into 2008. 
 
Table 8. Total costs for hospitalized care in the acute stage (NOK in 2008) 
 Cost per day1, 2 Hospitalized day(s) Total
1st line respondent 2,611 28 73,101
2nd line respondent 2,611 56 146,202
 
In the maintenance stage, the 2nd line respondents with acute relapse were considered to have a 
longer stay in hospital than the 1st line respondents with acute relapse. The length of 
hospitalization for the 1st line and 2nd line respondents are 30 days and 60 days, respectively 
referred to expert opinion (75). The length of hospitalization for 3rd line (clozapine) patients is 
assumed to equal to the 2nd line respondents (60 days). In the maintenance stage, after leaving 
the hospital the patients receive the CBC post-hospital relapse management and the residential 
care for the reminding days in the 3 month cycle. Thus, the 1st line respondents spend 60 days in 
the residential care while the 2nd line respondents expend 30 days in residential care.  
 
Table 9. Total costs for hospitalized care in 3 months in the maintenance stage (NOK in 2008) 






residential care3 Total 
1st line respondent 30 78,323 17,512 9,907 105,742
2nd line respondent 60 156,645 17,512 4,954 179,111
1. The cost per day of hospitalized care referred to NOK 2,611 (2). 
2. Table 6 
3. Table 7 
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4.4.5. Suicide-related cost 
The first strategy was to find default costs of suicide attempt based on the Norwegian diagnosis-
related group14 (DRG) code; poisoning and toxic effects of drug. However, since no such code 
existed in Norwegian DRG, I referred the direct costs of suicide death and suicide attempts in 
U.S. Based on over 32,000 of completed suicides and 109,500 hospitalizations for suicide 
attempts in 1994, the direct cost of suicide attempt was US$ 1,860 and the direct cost of suicide 
death was US$ 575 (96). In 2008, they were NOK 15,891 and NOK 4,913, respectively with 
reflecting currency rate (US$ 1=NOK 7.1) and CPI inflation. 
 
4.4.6. Drop out cost 
Although some of the patients with schizophrenia drop out of clinical trials and the researcher 
fail to track them down, they are likely to continue other types of treatment. Thus, the health 
care resource consumed by the drop out patients was assumed the patients would suffer from 
uncontrolled symptoms and remain in hospitalized care all the following cycles. The drop out 
costs for the first year was multiplied with the daily inpatient cost, NOK 2,611 per day for 365 
days. From the second and fifth year, the drop out costs was four times more than the first year 
cost. Since there was uncertainty in association with the drop out cost, one-way sensitivity 












                                                 
14 Diagnosis-related group (DRG) is a system to classify hospital cases into one of pre-defined diagnosis groups. 
DRG is based on ICD 10 diagnoses, procedures, age, sex, discharge status, and the presence of complications or 
comorbidities. 
 36
Table 10. Cost per schizophrenic patient in Norway (NOK in 2008) 
    NOK Sources 
Acute stage   
Drug Cost   
 Olanzapine, 8weeks 1,707 (58) 
 Risperidone, 8weeks 849 (58) 
 Olanzapine switched from risperidone, 16weeks 2,556 (58) 
 Risperidone switched from olanzapine, 16weeks 2,556 (58) 
Hospitalized care (HC) cost   
 1st line respondent (28 days) 73,101 (2) 
 2nd line respondent (56 days) 146,202 (2) 
Maintenance stage (3 months)   
Drug Cost    
 Olanzapine 10mg 2,743 (58) 
 Risperidone 4mg 1,364 (58) 
 Clozapine 300mg 1,162 (58) 
 Biperiden 2mg, olanzapine user by 1st year 14 (58), (51), (95) 
 Biperiden 2mg, risperidone user by 1st year 25 (58), (51), (95) 
 Biperiden 2mg, olanzapine user from 2nd year 6 (58), (90), (92) 
 Biperiden 2mg, risperidone user from 2nd year 9 (58), (90), (92) 
Community based care cost   
 Clinical management, symptoms stable 6,011 (97) 
 Clinical management, acute relapse 17,600 (97) 
 Residential care 14,861 (2) 
Hospitalized care cost   
 1st line respondent (30 days) 105,742 (2) 
 2nd  line respondent (60 days) 179,111 (2) 
Suicide cost   
 Suicide attempt 15,891 (96) 
  Suicide death 4,913 (96) 
Drop out  cost (2) 
     The first year (365 days) 791,911 (2) 









5.1. Costs and health consequences 
In the first year, the total expected cost per schizophrenic patient with olanzapine was NOK 
549,740 which was NOK 13,131 lower than risperidone (NOK 562,871). From the second to 
fifth year, the expected total cost per schizophrenic patient with olanzapine was NOK 1,328,332, 
which was NOK 52,665 lower than risperidone (NOK 1,380,997). The annual average cost per 
schizophrenic patient using both olanzapine and risperidone were about 39% deceased 
compared to the total expected cost in the first year. The total five-year expected cost per 
schizophrenic patient with olanzapine was NOK 1,878,072 which was NOK 65,796 lower than 
risperidone (NOK 1,943,868). 
 
Table 11. The total expected costs (NOK in 2008) 
  1 year 2-5 year Annual average from 2nd year Total
Olanzapine 549,740 1,328,332 332,083 1,878,072
Risperidone 562,871 1,380,997 345,249 1,943,868
Incremental cost 13,131 52,665 13,166 65,796
 
In the first year, the total expected PANSS reductions were 112.60 and 111.55 for olanzapine 
and risperidone, respectively. The expected incremental costs for risperidone were NOK 13,131 
and the expected incremental effectiveness for risperidone was -1.05. Therefore, olanzapine was 
a dominant alternative to risperidone. 
 
Table 12. Cost effectiveness analysis results in the first year (NOK in 2008) 
Strategy Cost ΔC Effectiveness ΔE C/E ICER 
Olanzapine 549,740 - 112.60 PANSS - 4,882 NOK/PANSS - 
Risperidone 562,871 13,131 111.55 PANSS -1.05 PANSS 5,046 NOK/PANSS Dominated 
* ICER refers to [Equation 1]. 
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 Figure 4. Cost-Effectiveness Analysis on schizophrenic patients with olanzapine and risperidone
 
5.2. Sensitivity analysis 
Although the Cochrane meta-analysis provided the most of data used in the model, several 
parameters of probability and cost still seemed to contain uncertainty, especially, the parameters 
which were estimated by experts’ opinion or assumed. Sensitivity analysis was aimed at firstly 
identifying and representing factors involved with uncertainty. Secondly, it was aimed at finding 
the most sensitive variables and reporting the weakness of the model. The third was to test 
impacts of difference between the adequate and mild respond to the antipsychotics in the model 
to glance schizophrenic patients with adequate respond in the real practice. Lastly, PSA using 
Monte Carlo simulation was conducted to report incorporative results involving all of the 
uncertain parameters.  
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5.2.1. One-way sensitivity analysis 
In the model, the probability of acute relapse to compliant patients with olanzapine (P=0.098) 
was relatively high to the probability of acute relapse to compliant patients with risperidone 
(P=0.365) in the first year. To examine the sensitivity of the probabilities, one-way sensitivity 
analysis was conducted within a range of the acute relapse rate, 0.00 to 0.50. The amount of 
WTP was assumed to be NOK 5,000. One-way sensitivity analysis on the probability of acute 
relapse to compliant patients with olanzapine resulted in no a crossing point, threshold that 
represents a change in the optimal strategy in the NMB-the probability plane (Figure 4). One-
way sensitivity analysis on the probability with risperidone resulted also the NMB-the 
probability plane with no threshold point. As a result, it was concluded that the probabilities of 
acute relapse to compliant patients with olanzapine and risperidone do not change the optimal 
alternative in the model.  
 
 
Probability of acute relapse for compliant patients with olanzapine 
Figure 5. One-way sensitivity analysis on the probability of acute relapse to compliant patients with 
olanzapine (WTP=5,000), NMB refers to [Equation 2] 
 
One-way sensitivity analysis examined other variables which referred to estimates or 
assumptions in other studies. The probability of acute relapse to noncompliant patients with 
olanzapine, the probability of acute relapse to noncompliant patients with risperidone and the 
probability of hospitalized care were tested but threshold points were not found, either. All of 
the results with the variables are summarized in a Tornado gram (Appendix V).  
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5.2.2. Tornado diagram 
As a set of one-way sensitivity analyses, Tornado diagrams compare each impact of costs and 
probability parameter on the results. Figure 6 includes the relevant cost parameter in the first 
year where low and high input were set by +/- 30% of the cost estimates. Considering the 
potential of overestimating, differently with the drop out cost parameter, the low input was half 
of the drop out cost and the high input was the drop out cost value itself. The wide bars indicate 
that the variables have a large potential effect on the expected values of in the model. The result 
is summarized in Table 13 ranked with the ten broadest spread of cost parameters. 
 
 
Figure 6. Tornado diagram with cost parameters in the first year, WTP=5,000 (NOK in 2008) 
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Table 13. Cost parameters ranked by the ten broadest spread in the first year, WTP=5,000 (NOK in 
2008) 
Rank Parameters Low Input High Input Spread
1 Cost dropout first year 395,955 791,911 118,186
2 Cost mild respond 2nd line hospitalized care 125,377 232,844 74,696
3 Cost acute stage hospitalization 2nd line 102,341 190,062 33,853
4 Cost adequate respond 2nd line hospitalized care 125,377 232,844 14,257
5 Cost mild respond community based care residential care 10,402 19,319 14,061
6 Cost acute stage hospitalization 1st line 51,170 95,031 13,842
7 Cost adequate respond community based care residential care 10,402 19,319 7,774
8 Cost mild respond 1st line hospitalized care 74,019 137,464 7,692
9 Cost adequate respond 1st line hospitalized care 74,019 137,464 5,591
10 Cost mild respond community based care clinical management stable maintenance 4,207 7,814 4,426
* A list with all of the cost parameters is presented in Appendix VI. 
 
Among the cost parameters, the drop out cost had the largest impact on the results in the first 
year. However, the size of the drop out cost did not vary the optimal alternative in this study. In 
a one-way sensitivity analysis on drop out cost (Figure 7), the incremental cost between 
olanzapine and risperidone is gradually becoming smaller as corresponding the drop out cost 
becomes lower. However, even if the drop out cost is zero, the incremental cost was NOK 2,643 
(Table 14) and risperidone is a still dominated by olanzapine.  
 
 
Figure 7. One-way sensitivity analysis on the drop out cost in the first year, WTP=5,000 (NOK in 2008) 
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Table 14. One-way sensitivity analysis on the drop out cost in the year, WTP=5,000 (NOK in 2008) 
Drop out cost Strategy Cost ΔC Effectiveness ΔE ICER 
0 Olanzapine 313,368 - 112.60 - - 
 Risperidone 316,011 2,643 111.55 -1.05 Dominated 
158,382 Olanzapine 360,643 - 112.60 - - 
 Risperidone 365,383 4,740 111.55 -1.05 Dominated 
475,147 Olanzapine 455,192 - 112.60 - - 
 Risperidone 464,127 8,935 111.55 -1.05 Dominated 
791,911 Olanzapine 549,740 - 112.60 - - 
 Risperidone 562,871 13,131 111.55 -1.05 Dominated 
 
In the Tornado diagram with the cost parameters, the cost for 2nd line hospitalized care in the 
maintenance stage appeared as the second most influential parameter to vary results. The 
following parameters are presented in ascending order; the 2nd line hospitalization in the acute 
stage, CBC residential care, 1st line hospitalized care in the maintenance stage, CBC stable 
maintenance care and CBC acute relapse care. Given the threshold of NOK 5,000, none of the 
cost parameters in the Tornado diagram in Figure 6 implied to switch the optimal alternative  
 
Spreads of drug costs were quite small relatively to the other parameters (Figure 5). This result 
accorded with previous reports that the inpatient costs accounted for 78 to 94% of total 
treatment costs (98) and about 75% of the costs of schizophrenia treatment were due to inpatient 
or residential care, while drugs represent less than 5% (99).  
 
Among probability parameters in the first year of the model, the drop out probability for 
olanzapine and the drop out probability for risperidone had the first and second most influence 
(table 15). The difference between low and high input of the range with probability parameters 
was 0.2 or 0.3.The Tornado diagram with probability parameters brought the results with 
threshold points. The threshold points were marked as black lines in the bars to indicate shifting 





Table 15. Probability parameters ranked by the ten broadest spread in the first year, WTP=5,000 (NOK 
in 2008) 
Rank Parameters Low Input High Input Spread 
1 Probability risperidone drop out 0.1 0.3 9,731,224
2 Probability olanzapine drop out 0.1 0.3 9,236,100
3 Probability olanzapine adequate respond 0.1 0.3 6,185,932
4 Probability olanzapine inadequate respond  0.4 0.6 4,904,604
5 Probability risperidone adequate respond  0.1 0.3 4,062,491
6 Probability risperidone inadequate respond 0.4 0.6 3,896,226
7 Probability olanzapine intolerable adverse events 0.0 0.2 3,554,748
8 Probability risperidone intolerable adverse events 0.0 0.2 2,476,877
9 Probability risperidone suicide attempt 0.0 0.2 1,787,497
10 Probability clozapine suicide attempt 0.0 0.2 1,444,414
* A list with all of the probability parameters is represented in Appendix VII. 
 
Figure 8. Tornado diagram with probability parameters in the first year, WTP=5,000 (2008 in NOK) 
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The following three probability parameters included threshold points switching the optimal 
alternative; drop out for olanzapine, drop out for risperidone, and inadequate respond for 
risperidone (Table 16). 
 
Table 16. Summary of results of one-way analysis on probability analysis 
Parameter Range Threshold Optimal alternative 
Probability of drop out for olanzapine 0,10-0,30 0,22 Olanzapine: 0.10-0.22 Risperidone: 0.22-0.30 
Probability of drop out for risperidone  0,10-0,30 0,19 Risperidone: 0.10-0.19 Olanzapine: 0.19-0.30 
Probability of inadequate respond for  risperidone 0,40-0,60 0,47 Risperidone: 0.40-0.47 Olanzapine: 0.47-0.60 
 
In the one-way sensitivity analysis on the probability of drop out for olanzapine, olanzapine has 
the highest net benefit between 0.10 and 0.22, risperidone has the highest net benefit between 
0.22 and 0.30 (Figure 9.1). In the one-way sensitivity analysis on the probability of drop out for 
risperidone, risperidone has the highest net benefit between 0.00 and 0.19, while olanzapine has 
the highest net benefit between 0.19 and 0.30 (Figure 9.2). Lastly, in the one-way sensitivity 
analysis on the probability of inadequate respond for risperidone, risperidone has the highest net 
benefit between 0.40 and 0.47, while olanzapine has the highest net benefit between 0.47 and 
0.60 (Figure 9.3).  
 
 
*P-OL-DO: Probability of drop out for olanzapine / *EV: expected value 
 




*P-RI-DO: Probability of drop out for risperidone 
 
Figure 9.2. One-way sensitivity analysis on the probabilities of drop out, risperidone, NMB 
(WTP=5,000) 
 
*P-RI-IAR: Probability of inadequate respond for risperidone 
 
Figure 9.3. One-way sensitivity analysis on the probabilities of inadequate respond for risperidone, NMB 
(WTP=5,000) 
 
In general, the results presented in the Tornado diagram from the second to fifth year were 
nearly similar with the results from the first year. The text report of the Tornado diagram with 
cost and probability parameters from the second to fifth year is represented in Appendix VIII. 
The drop out cost for 4 years appeared as the parameter having the highest impact on the results 
but did not include the threshold points. Hence, olanzapine still dominated risperidone. The 
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results from the one-way sensitivity analysis of the following three probabilities; the probability 
of drop out for olanzapine, the probability of drop out for risperidone and the probability 
inadequate respond for risperidone, are presented in Appendix IX. 
 
5.2.3. Two-way sensitivity analysis 
Two-way sensitivity analysis was used to examine the impact of simultaneous changes in the 
values of two variables. Figure 10 shows the result of the two-way sensitivity analysis on the 
probability of drop out for olanzapine and the probability of drop out for risperidone in the first 
year. The planes occupied by discreet colors indicated the chance for alternatives to be optimal 
with the highest NMB. So, since risperidone occupies more than half of the plane in the graph, it 
was interpreted that if the probability of drop out for risperidone is the same or even slightly 
higher than that for olanzapine, risperidone is an optimal alternative with the highest NMB.  
 
 
Figure 10. Two-way sensitivity analysis on the probability of drop out for olanzapine and the probability 
of drop out for risperidone in the first year, NMB (WTP=5,000) 
 
5.2.3. One-way sensitivity analysis on adequate respond parameters  
In model, the treatments responds were defined into three different sub-responds; adequate, mild 
and inadequate. Since the inadequate respond, along with the intolerable adverse events, was a 
pathway forward to switching to the 2nd or 3rd line treatment, the role of inadequate respond was 
discreet to that of adequate and mild respond. However, because there was no difference made 
in further branches’ probability and cost parameters of between adequate and mild respond, the 
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role of adequate and mild respond were not discreet in the model. Hence, one-way sensitivity 
analysis varied values of parameters with the adequate respond which were initially recorded 
same as parameters with the mild respond and examined the changes on the results.  
 
One-way sensitivity analysis examined the cost parameter of hospitalized care for the 1st line 
respondent with the adequate respond in the maintenance stage (Figure 11). Risperidone is an 
optimal alternative with the highest NMB, under the condition that the costs of hospitalized care 
for the 1st line respondent with the adequate respond are less than NOK 40,000 which are 
equivalent to the total costs of 5.14 days hospitalized care including post hospital CBC and post 
hospital residential care. Initially, the length of hospitalization for the 1st line respondent and the 
2nd line respondent were 30 days and 60 days, respectively (Table 9). 
 
Cost of hospitalized care for the 1st line respondent with the adequate respond
Figure 11. One-way sensitivity analysis on cost of hospitalized care for the 1st line respondent with the 
adequate respond, NMB (WTP=5,000) 
 
However, one-way sensitivity analysis for the cost parameter of hospitalized care for the 2nd line 
respondent with the adequate respond did not result in threshold points. (Appendix X). The one-
way sensitivity analysis examined the other parameters involved with adequate respond; the cost 
of CBC non-hospital relapse management for the adequate respondent, the probability of 
noncompliance for adequate respondent, the probability of acute relapse to the compliant patient 
with the adequate respond, the probability of acute relapse to the noncompliant patient with the 
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adequate respond and the probability of acute relapse for the adequate respondent. The results 
came out with no change in the optimal alternative, either. 
 
5.3. Probability Sensitivity Analysis using Monte Carlo simulation 
In this study, all of the cost and probability parameters were incorporated into the PSA using 
Monte Carlo simulation and the parameters were defined in as probability distributions to reflect 
their uncertainty. The probability parameters which referred to the Cochran meta-analysis were 
defined as beta distribution, integer form and the probability parameters, which referred to 
expert’s opinion or estimates were defined as beta distribution, real number form or uniform 
distribution. Also, the cost parameters were defined as uniform distribution or gamma 
distribution. The input parameters in the PSA are summarized with the type of distribution and 
their values in Appendix XI and XII. In the PSA, Monte Carlo simulation propagated input 
parameters 2,000 times within randomly sampled from the probability distributions and 
produced in following results. 
 
The 2,000 pairs of the total cost and effectiveness with olanzapine and risperidone were quite 
widely scattered. The mean total cost for olanzapine at the first year was NOK 494,897 and it 
was still lower than the mean total cost for risperidone at the first year (NOK 502,704). The 
mean PANSS reduction for olanzapine was 0.91 higher than risperidone. However, with 95% 
confidence interval, the total cost for olanzapine was NOK 342,807 to 706,504 and the total cost 
for risperidone was NOK 344,428 to 725,844. The effectiveness of olanzapine was 105 to 120 
and that of risperidone was 104 to 120 (Table 17). 
 
Table 17. The PSA results with cost (NOK in 2008) and effectiveness (the PANSS reduction) 
 Costs (mean) Effectiveness (mean) 
Olanzapine 342,807 – 706,504 (494,897) 105 – 120 (112.79) 
Risperidone 344,428 – 725,844 (502,704) 104 – 120 (111.88) 
* 95% confidence level: 2.5% - 97.5% 
 
The ICE scatterplot was conducted to visualize the spread of pairs of incremental cost and 
effectiveness values from the simulation results in the PSA. As a setting of ICE scatterplot with 
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95% confidence interval, the comparator was olanzapine and the baseline was risperidone. In the 
incremental cost-effectiveness plane when WTP is NOK 5,000 (Figure 12), 1,151 points 
(55.55%) belonged to Section 1 (Table 18) which the olanzapine dominates risperidone (referred 
to Figure 2). 482 points (24.0%) belonged to Section 5 which the risperidone is an optimal 
alternative. 183 points (9.2%) belonged to Section 2 which the olanzapine is cost effective. 179 
points (9.0%) belonged to Section 6 which risperidone dominates olanzapine. The rest of the 
pairs (0.3%) belong to Section 3 which olanzapine is optimal 
 
Table 18. The PSA results with the ICE Scatterplot (Number of sample=2,000, WTP=5,000) 
Section 1 2 3 4 5 6 Indifference
Points (N) 1,151 183 5 0 482 179 0
Percent (%) 57.6 9.2 0.3 0.0 24.1 9.0 0
 
In summary, the chance of olanzapine being an optimal alternative in the model is 67.1% (sum 
of points in Section1 to 3, where the comparator is chosen as an optimal alternative). The ICE 
isocontours graph shows the relative concentration of points in the scatterplot (Figure 12). 
 
 
* Cost tolerance (+/-): 1, Effect tolerance (+/-): 0.01 
 
Figure 12. ICE Scatterplot of Olanzapine vs. Risperidone, and the ICE isocontours graph (WTP=5,000) 
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Chapter 6 
DISCUSSION AND CONCLUSION 
 
One of the strengths in the decision analytic model was to embrace critical factors in modelling 
schizophrenia. Martin Knapp pointed out follow three factors as mostly influencing costs of 
schizophrenia; non-adherence to medication, relapse and in-patient admissions (100). In a 
review of pharmacoeconomic modelling in schizophrenia (72), following confounding factors 
which increase or decrease the ICE and the ICER were suggested; relapse, compliance, 
institution, drop out and switch. In this study, the model involved all of those factors together 
with other important factors, such as different degree of responds to the antipsychotics, adverse 
events and suicide risk. Another strength was to preserve objectivity with the methods that most 
of the data on probability and effectiveness were based on the extensive meta-analysis. The third 
was that the model presented the incorporative results involving uncertainty surrounding all 
parameters by the PSA using Monte Carlo simulation.  
 
The results of this study were compared with other CEAs of olanzapine and risperidone, which 
were reported by a systematic review (40). Palmer 1998 (76), De Hert 2000 (101) and Almond 
2000 (102) analyzed the cost-effectiveness by means of a Markov model and concluded that 
olanzapine was more costly than risperidone; however, olanzapine considered to increase 
effectiveness at reasonable cost. Kasper 2000 (103), Loos 2000 (104) and Martin 2000 (105) 
concluded that olanzapine was more cost-effective than risperidone and Edgell 2000 (106) 
argued that olanzapine dominated risperidone. On the other hand, Bille 1999 (107) and 
Duchesne 1999 (108) reported that risperidone more cost-effective than olanzapine. 
 
The most problematic issue of the model was probably to refer to German experts’ opinion for 
proportion of use, for example, the number of visit to psychiatrist and/or psychologist, GP and 
out patient clinic in CBC, and the proportion of use in the residential care and the probability of 
hospitalized care. Although one-way sensitivity analysis and the PSA examined the uncertainty 
with the values referred, it might still be the most severe weakness in the model. Further studies 
will have to verify the feasibility of adapting the sources estimated in Germany. Another issue is 
population characteristics in the clinical trials. In this study, the effectiveness of the 
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antipsychotic referred to Conley 2001 (71) (n=497; M=274/F=103) and Jeste 2003 (78) (n=175; 
M=64/F=113) and the probability of acute relapse was based on Namjoshi 2002 (94) (n=364; 
M=259/F=105). All of those studies were randomized and double-blind clinical trials in the 
United States. However, while the mean age of the Conley study group was 39.9 years (SD=11) 
and that Namjoshi study group was 39.4 years, the mean age of the Jeste study group was over 
71 years. Since Jeste and his colleges aimed to study risperidone and olanzapine in elderly 
patients with schizophrenia and schizoaffective disorder, the single use of effectiveness data 
from the Jeste’s study seemed doubtful to generalize into the population with schizophrenia in 
Norway.  
 
The olanzapine and risperidone seemed the appropriate comparators as the most frequently 
prescribed for schizophrenia in Norway. Based on Norwegian Prescription Database in 2007, 
olanzapine was used by 15,637 users which was the highest number of the users among 
antipsychotics for schizophrenia treatment and quetiapine (n=8,310), risperidone (n=7,891), 
haloperidol (n=4,803), zuclopenthixol (n=3,196) and clozapine (n=2,098) followed after in 
Norway (9). Quetiapine, which is an atypical antipsychotic used in the management of 
schizophrenia and bipolar I disorder, and used off-label for a variety of other purposes, 
including insomnia and anxiety disorders, was also regarded as a popular alternative for 
schizophrenia treatment in Norway. So, further extended studies including other alternatives for 
schizophrenia are needed to capture overall antipsychotic medication practice in Norway.  
 
The decision analytic model also has limits. In the maintenance stage, there was no way out of 
the 3 months cycle except ending in suicide death. However, it might have been more realistic if 
the model had terminal nodes including comorbidity with schizophrenia. The percentage of 
people with schizophrenia showing at any point in time clinically significant depressed mood is 
at least 25% (109) and the patients experiencing depression when in remission from a psychotic 
episode, at a time of increasing insight into their illness, are at high risk of suicide (13). Beside, 
lifetime prevalence of substance abuse or dependence in persons with schizophrenia has been 
estimated at over 30% for alcohol and around 25% for illicit drugs in the United States (110) 
and the impact of comorbidity with substance abuse is significant in reducing treatment 
effectiveness, worsening positive psychotic symptoms, increasing social disability and raising 
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the likelihood of violence (111). Cardiovascular diseases and HIV infection also has reported 
with increasing frequency, prevalence rates in schizophrenia patients (13). A model of 
antipsychotic medications for schizophrenia including comorbidity might bring out increased 
total costs per schizophrenic patient due to other illness caused it would decrease the value of 
NMB. 
 
According to HTA reports on antipsychotics for schizophrenia (40), the antipsychotics cause 
various types of side effects such as movement disorders, sedation, autonomic effects, 
gastrointestinal effects, weight gain, prolactin-related problems and cardiotoxic effects. 
According to the Cochrane meta-analysis (1), risperidone caused significantly more following 
side effects; insomnia, headache, constipation, abnormal ejaculation, agitation and backache. 
Olanzapine caused significantly more dry mouth15 and in terms of gain weight, olanzapine 
resulted in the twice higher chance of gaining weight in both short term and long term clinical 
trials than risperidone. In this study, the model included only EPSs as side effects caused by the 
antipsychotics. The WHO schizophrenia report suggested only EPSs as the side effect 
represented serious problems and deserved special attention while the most of the side-effects 
are mild and time-limited (13). However, it might be still necessary to include other side effects 
as long as they appear with significant difference between olanzapine and risperidone, in order 
to perform such a limited project which requires identifying delicate differences. 
 
This study has also following issues in identifying costs for schizophrenia patients. The model 
has risk to underestimate the costs for schizophrenic patients because not only with the problem 
to include all of the different treatments for schizophrenia but difficulty to update all of the 
newly introduced treatments in Norway. In 2001, Day treatments and home care for any kind of 
illness occupied 8.6% of the total health expenditure in Norway (112). The cost of day treatment 
for schizophrenic patients could refer to the partial sheltered accommodation (2) but the cost 
data of home care services offered by both public and private providers were not available in 
Norway. In addition, to comply with the economic principle measuring cost as opportunity 
cost16, it might be necessary to include the cost for the voluntary services for schizophrenia in 
                                                 
15 Xerostomia is a medical term for dry mouth. 
16 Opportunity cost or economic opportunity loss is the value of the next best alternative foregone as the result of 
making a decision (105). 
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Norway. For example, the opportunity cost of a counselor who volunteers services to a 
schizophrenia treatment could be the salary earned in a paid position.  
 
Second, the costs estimated in 1999 were likely to differ with the actual cost in 2008 due to 
changes having been introduced in the mental health service environment. In Norway, like the 
most western countries, the services for people with mental health problems have gone through 
major changes over the last decades (113). In 1998, the Norwegian Parliament introduced a 
national mental health programme, calling for a major increase in the funding of mental health 
related services as well as a major reorganization of these services and implementation of the 
programme took place between 1999 and 2008  (114). The increase in the funding would 
expand the total volume of health resource consumed for mental patients, perhaps schizophrenia 
patients as well. Another main change in the mental health care in Norway was that the 
reorganization, which was aimed at strengthening community based services and diversifying 
the contents of those services for sufficient preventive measures and planning, coordination and 
monitoring on discharge follow-ups for mental patients, was likely to magnify expenses in 
community based care for schizophrenia in Norway. However, the reorganization not 
necessarily reduced hospital wards and specialized care for psychiatric patients, rather those 
institutions had been expanded as mental health services were lacking at all level and 
accessibility to specialized services was inadequate and inpatient stays were often too short 
(106). Furthermore, a factor to alter mostly the environment of mental health services might be a 
series of wide-ranging reforms designed to make greater use of market mechanisms in health 
care system in Norway. For example, competition has been introduced among health care 
providers by controlling the DRG base reimbursement and block grants and the number of 
contracts between municipalities and private health providers have been increased. Also out-of-
pocket payments have gradually raised and private insurance newly entered the health care 
industry in Norway. Hence, applying inflation rate with CPI was a limited method to reflect all 
of the changes which might have varied costs of schizophrenia treatment services in Norway. 
 
Third, the total expected cost per schizophrenic patient would be more extensive with a 
patient/family perspective of or a societal perspective since these perspectives should be 
concerned with indirect costs of schizophrenia. While direct costs associated with schizophrenic 
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patients were NOK 1.8 million, indirect costs associated with schizophrenic patients were NOK 
1.7 million in Norway (7). The indirect costs were based on the finding that 80% of patients 
with schizophrenia were without regular work while the 20% would work if they had not had 
this disease (99) but the amount could have been more if other issues surrounding schizophrenia 
were included as Martin Knapp argued that hidden costs to people with schizophrenia 
themselves, to their families and caregivers and to society are often substantial (100). Not only 
financial losses such as out of pocket payments for treatment, transport costs and lost income 
due to employment difficulties but social disability, social stigma17 and burden on caregivers 
could be considered as substantial costs. Considering the potential of the indirect cost, the total 
expected costs per schizophrenic patients in the model were perhaps a tip of iceberg.  
 
Finally, cost-effectiveness analysis is limited with a basic form of measuring health 
consequences of a programme as specific units such as the PANSS. Because the measure of 
primary effectiveness may differ from programme to programme, cost-effectiveness analysis 
can not be used to make comparisons across a broad set of interventions (68). Moreover, a more 
critical issue is whether the specific measuring unit is indeed equivalent to a purpose of 
introducing the health programme or not. Therefore, in this study, accordance of the PANSS 
reduction to utility of the schizophrenic patients is a matter of the utmost concern to assess 
whether the results based on NMB/WTP produced by the model are valuable or not. In fact, 
health state preferences of patients for schizophrenia were measured by a standard gamble 
approach (115) but only few data were available on utility weights for health states specific to 
the area of schizophrenia (75). However, mostly, the PANSS along with measurements for side 
effects seemed exchangeable with quality of life (QOL). In a conceptual modelling study, the 
author argued appropriate conceptual models of QOL for schizophrenia could be developed with 
standardized scales including the PANSS, abnormal involuntary movements scale (AIMS), 
Hillside Akathisia scale (HAI), and the social performance schedule (SPS) (116). Leslie and 
colleagues suggested that utility mapping function with schizophrenia could be created by using 
the PANNS and a set of health states including the presence of common adverse effects of 
medication (117). In their study of estimating utility gains with effective treatment of 
                                                 
17 Social stigma refers to a set of deeply discrediting attributes, related to negative attitudes and beliefs towards a 
group of people, likely to affect a person’s identity and thus leading to a damaged sense of self through social 
rejection, discrimination and social isolation (Goffman, 1963) 
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schizophrenia (118), 36-Item Short-Form Health Survey (SF-36) and the Extrapyramidal 
Symptom Rating Scale (ESRS) were additionally used with the PANSS to measure movement 
disorder severity. 
 
Considering all of the uncertainties surrounding the costs and effectiveness of the olanzapine 
and risperidone, the model could not conclude that olanzapine was more cost-effective than 
risperidone in Norway. For more precise results, further clinical trials are recommended to 
follow up patients who drop out of the study and evaluate relapse rates categorized into 
compliant and noncompliant patients distinctively. However, the model seemed capable to 
figure the overall total costs per schizophrenic patient treated with antipsychotic medications in 
Norway. In addition, the model can be used to provide a basic frame of modelling patients with 
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[Appendix I] Diagnosis of schizophrenia in the International Statistical Classification of Diseases and 
Related Health Problems 10th Revision (ICD-10) 
 
A minimum of one very clear symptom belonging to any one of the groups listed below as (a) to (d) or symptoms 
from at least two of the groups referred to as (e) to (i) should have been clearly present for most of the time during a 
period of 1 month or more. 
 
a) Thought echo, thought insertion or withdrawal and thought broadcasting.  
 
b) delusions of control, influence or passivity, clearly referred to body or limb movements or specific thoughts, 
actions or sensations; delusional perception. 
 
c) hallucinatory voices giving a running commentary on the patient’s behaviour or discussing the patient among 
themselves, or other types of hallucinatory voices coming from some part of the body. 
 
d) persistent delusions of other kinds that are culturally inappropriate and completely impossible, such as religious 
or political identity, or superhuman powers and abilities (e.g. being able to control the weather or being in 
communication with aliens from another world). 
 
e) persistent hallucinations in any modality, when accompanied either by fleeting or halfformed delusions without 
clear affective content or by persistent over-valued ideas, or when occurring every day for weeks or months on end. 
 
f) breaks or interpolations in the train of thought, resulting in incoherence or irrelevant speech, or neologisms. 
 
g) catatonic behaviour, such as excitement, posturing. or waxy flexibility, negativism, mutism and stupor. 
 
h) ‘negative’ symptoms such as marked apathy, paucity of speech and blunting or incongruity of emotional 
responses, usually resulting in social withdrawal and lowering of social performance; it must be clear that these are 
not due to depression or neuroleptic medication. 
 
i) a significant and consistent change in the overall quality of some aspects of personal behaviour, manifest as loss 




[Appendix II] Diagnosis of schizophrenia in the Diagnostic and Statistical Manual of Mental Disorders, 
4th Edition (DSM-IV) 
 
A. Characteristic symptoms: Two or more of the following, each present for a significant portion of time during a 
1-month period, or less if successfully treated: 1) Delusions, 2) Hallucinations, 3) Disorganized speech, e.g. 
frequent derailment or incoherence, 4) Grossly disorganized or catatonic behavior, 5) Negative symptoms, i.e. 
affective flattening, alogia or avolition. Note: Only one criterion A symptom is required if delusions are bizarre or 
hallucinations consist of a voice keeping up a running commentary on the person’s behaviour or thoughts, or two or 
more voices conversing with each other. 
 
B. Social/Occupational dysfunction. For a significant portion of the time since the onset of the disturbance, one or 
more major areas of functioning such as work, interpersonal relations, or self-care are markedly below the level 
achieved prior to the onset (or when the onset is in childhood or adolescence, failure to achieve expected level of 
interpersonal, academic or occupational achievement).  
 
C. Duration. Continuous signs of the disturbance persist for at least 6 months. This 6-month period must include at 
least 1 month of symptoms (or less if successfully treated) that meet criterion A, i.e. active-phase symptoms, and 
may include periods of prodromal or residual symptoms. During these prodromal or residual periods, the signs of 
the disturbance may be manifested by only negative symptoms or two or more symptoms listed in criterion A 
present in an attenuated form (e.g. odd beliefs, unusual perceptual experiences). 
 
D. Schizoaffective and mood disorder exclusion. Schizoaffective and mood disorders have been ruled out because 
either (1) no major depressive, manic or mixed episodes have occurred concurrently with the active-phase 
symptoms or (2) if mood episodes have occurred during active-phase symptoms, their total duration has been brief 
relative to the duration of the active and residual periods. 
E. Substance/general medical condition exclusion. The disturbance is not related to the direct physiological effect of 
a substance (e.g. a drug of abuse, a medication) or a general medical condition.  
 
F. Relationship to a pervasive developmental disorder. If there is a history of autistic disorder or another pervasive 
developmental disorder, the additional diagnosis of schizophrenia is made only if prominent delusions or 








[Appendix III] A summary of studies used as source providing effectiveness and probabilities  
 
Author/year Population Duration Intervention Allocation concealment 
Chan 2003 N=60 8 weeks 1. Risperidone: dose range 0.5-6 mg/day. N=30. B-Unclear 
   2. Olanzapine: dose range 2.5-20 mg/day. N=30.  
Conley 2001 N=407 8 weeks 1. Risperidone: dose range 2-6 mg/day, mean 4.78 mg/day. N=188. A – Adequate
   2. Olanzapine: dose range 5-20 mg/day, mean 12.43 mg/day. N=189.  
Harvey 2003 N=176 8 weeks 1. Risperidone: dose range 1-3 mg/day. N=87. B-Unclear 
   2. Olanzapine: dose range 5-20 mg/day. N=89.  
Jeste 2003 N=175 8 weeks 1. Risperidone: dose range 1-3 mg/day. N=87. B-Unclear 
   2. Olanzapine: lowest dose not stated, range ~5-20 mg/day. N= 88.  
Littrell 1999 N=24 one year 1. Risperidone: dose range 5.2 mg/day. N=12. B-Unclear 
   2. Olanzapine: dose range 19.2 mg/day. N=12.  
Ritchie 2003 N=66 4 weeks 1. Risperidone: dose not specified. N=32.  
   2. Olanzapine: dose not specified. N=34.  
Tran 1997 N=339 28 weeks 1. Risperidone: dose range 4-12 mg/day. N=167. A-Adequate 
   2. Olanzapine: dose range 10-20 mg/day. N=172.  
CATIE 2005 N=1460 52 weeks 1. Risperidone: dose 1.5 to 6mg/d. N=341. B-Unclear 
   2. Olanzapine: dose 7.5 to 30mg/day. N=336.  
   3. Quetiapine: dose 200 to 800 mg/day. N=337.  
   4. Perphenazine: dose 8 to 32 mg/day. N=261.  
   5. Ziprasidone: dose 40 to 160 mg/day. N=185.  
Keefe 2005 N=414 52 weeks 1. Risperidone: dose range 2-10 mg/day. N=158. A-Adequate 
   2. Olanzapine: dose range 5 to 20 mg/day. N=159.  
   3. Haloperidol: dose range 2-19mg/day. N=69.  
Purdon 1998 N=65 54 weeks 1. Risperidone: dose range 4-10 mg/day. N=21. A-Adequate 
   2. Olanzapine: dose range 5-20 mg/day. N=21.  
   3. Haloperidol: dose range 5-20 mg/day. N=23.  
Namjoshi 2002 N=364 52 weeks 1. Risperidone: dose range 2-10 mg/day. N=136. B-Unclear 
   2. Olanzapine: dose range 5-20 mg/day. N=143.  
      3. Haloperidol: dose range 2-9 mg/day. N=85.   





[Appendix IV] An explanatory estimating process for probabilities of acute relapse to compliant patients 
with olanzapine and risperidone 
 
According to a clinical trial (94), 19 of 143 patients (13.3%) with olanzapine were hospitalized and 39 of 136 
patients (28.7%) with risperidone were relapse/hospitalized by one year. I supposed that in the below figure, 13.3% 
of patients with olanzapine at the stable maintenance stage should be equal to the sum of the number of hospitalized 
patients with acute relapse to noncompliant patients with olanzapine (B) and the number of hospitalized patients 
with acute relapse to compliant patients with olanzapine (C). Suppose, the probability of acute relapse to compliant 
patients with olanzapine is X1, then the following formula is made. 
 
 
1. The number of patients in the stable maintenance. 
2. The probability of noncompliance referred to  (90), (91), (92), (51). 
3. The probability of acute relapse to noncompliant patients with olanzapine referred to (77) 
4. The probability of hospitalized care to referred to (75) 
5. The probability of being hospitalized to patients with olanzapine (94). 
 
B (=A*0.141*0.75*0.7) + C (=A*0.859*X1*0.7) = A*0.133  
 
So, X1 = 0.098 
 
Similarly, suppose, the probability of acute relapse to compliant patients with risperidone is X2, then the following 




1. The number of patients in the stable maintenance. 
2. The probability of noncompliance referred to  (90), (91), (92), (51). 
3. The probability of acute relapse to noncompliant patients with olanzapine referred to (77) 
4. The probability of hospitalized care to referred to (75) 
5. The probability of being hospitalized to patients with olanzapine (94). 
 
B (=A*0.115*0.75*0.7) + C (=A*0.88*X2*0.7) = A*0.287 
 
So, X2 = 0.365 
 
Hence, the probability of acute relapse to compliant patients with olanzapine is 0.098 and the probability of acute 






























 [Appendix VI] A list with all of the cost parameters in the first year in Tornado diagram (NOK in 2008) 
 
Rank Parameters Low Input High Input Spread 
1 Cost dropout first year 395,955 791,911 118,186
2 Cost mild respond 2nd line hospitalized care 125,377 232,844 74,696
3 Cost acute stage hospitalization 2nd line 102,341 190,062 33,853
4 Cost adequate respond 2nd line hospitalized care 125,377 232,844 14,257
5 Cost mild respond community based care residential Care 10,402 19,319 14,061
6 Cost acute stage hospitalization 1st line 51,170 95,031 13,842
7 Cost adequate respond community based care residential care 10,402 19,319 7,774
8 Cost mild respond 1st line hospitalized care 74,019 137,464 7,692
9 Cost adequate respond 1st line hospitalized care 74,019 137,464 5,591
10 Cost mild respond community based care clinical management stable maintenance 4,207 7,814 4,426
11 Cost mild respond community based care clinical management acute relapse 12,320 22,880 3,694
12 Cost adequate respond community based care clinical management stable maintenance 4,207 7,814 2,803
13 Cost mild respond drug clozapine 162 2,162 1,874
14 Cost mild respond drug olanzapine 1,742 3,742 1,458
15 Cost adequate respond olanzapine 10mg 3 month 1,742 3,742 1,060
16 Cost adequate respond, community based care clinical management acute relapse 12,320 22,880 999
17 Cost adequate respond risperidone 4mg 3months 364 2,364 622
18 Cost acute stage drug olanzapine risperidone mild respond 1,556 3,556 598
19 Cost mild respond drug risperidone 364 2,364 553
20 Cost acute stage drug olanzapine mild respond 707 2,707 365
21 Cost acute stage drug olanzapine adequate respond 707 2,707 265
22 Cost acute stage drug olanzapine to risperidone adequate respond 1,556 3,556 173
23 Cost suicide attempt 11,123 20,658 154







[Appendix VII] A list with all of the probability parameters in the first year in Tornado diagram (NOK 
in 2008) 
 
Rank Parameters Low Input High Input Spread 
1 probability risperidone drop out 0,1 0,3 9,731,224
2 probability olanzapine drop out 0,1 0,3 9,236,100
3 probability olanzapine adequate respond 0,1 0,3 6,185,932
4 probability olanzapine inadequate respond (less than 20 reduction in PANSS) 0,4 0,6 4,904,604
5 probability risperidone adequate respond(more than 40 reduction in PANSS) 0,1 0,3 4,062,491
6 probability risperidone inadequate respond(less than 20 reduction in PANSS) 0,4 0,6 3,896,226
7 probability olanzapine intolerable adverse events 0 0,2 3,554,748
8 probability risperidone intolerable adverse events 0 0,2 2,476,877
9 probability risperidone suicide attempt 0 0,2 1,787,497
10 probability clozapine suicide attempt 0 0,2 1,444,414
11 probability olanzapine suicide attempt 0 0,2 1,430,651
12 probability clozapine acute relapse 0,6 0,9 102,204
13 probability olanzapine adequate respond noncompliance 0 0,3 72,001
14 probability olanzapine mild respond noncompliance 0 0,3 65,393
15 probability olanzapine adequate respond compliance acute relapse 0 0,2 63,244
16 probability olanzapine mild respond compliance acute relapse 0 0,2 57,440
17 probability risperidone adequate respond compliance acute relapse 0,2 0,4 54,752
18 probability mild respond hospitalization 0,5 0,8 48,812
19 probability clozapine suicide death 0,3 0,5 41,595
20 probability olanzapine suicide death 0,2 0,5 40,851
21 probability risperidone suicide death 0,2 0,4 39,686
22 probability risperidone mild respond compliance acute relapse 0,2 0,4 32,695
23 probability risperidone adequate respond noncompliance 0 0,2 23,790
24 probability olanzapine adequate respond noncompliance acute relapse 0,6 0,9 15,572
25 probability risperidone mild respond noncompliance 0 0,2 14,206
26 probability olanzapine mild respond noncompliance acute relapse 0,6 0,9 14,143
27 probability risperidone acute relapse noncompliance acute relapse 0,6 0,9 10,658
28 probability adequate respond hospitalization 0,5 0,8 9,786






[Appendix VIII] The text report of the Tornado diagram with cost and probability parameters from the 
second to fifth year, (WTP=13,000) 
 
Rank Parameters Low Input High Input Spread 
1 cost dropout 4year 1500000 3167645 497,764
2 Probability olanzapine drop out 0.1 0.3 393,543
3 probability risperidone drop out 0.1 0.3 324,754
4 probability olanzapine inadequate respond 0.4 0.6 105,190
5 probability clozapine acute relapse 0 0.2 85,077
6 cost mild respond community based care residential care 10402 19319 61,654
7 cost mild respond 2nd line hospitalized care 125377 232844 59,438
8 probability olanzapine intolerable adverse events 0 0.2 49,979
9 probability mild respond hospitalization 0.5 0.8 41,314
10 probability risperidone adequate respond 0.1 0.3 38,763
11 probability risperidone inadequate respond 0.3 0.6 36,811
12 probability olanzapine mild respond noncompliance acute relapse 0 0.2 36,047
13 cost adequate respond CBC residential care 10402 19319 29,112
14 probability risperidone acute relapse noncompliance acute relapse 0 0.2 28,116
15 probability olanzapine adequate respond noncompliance acute relapse 0 0.2 26,203
16 cost mild respond CBC clinical management stable maintenance 4207 7814 23,788
17 probability risperidone mild respond compliance acute relapse 0.2 0.4 21,529
18 probability risperidone suicide attempt 0 0.2 17,253
19 cost mild respond 1st line hospitalized care 74019 137464 12,162
20 cost adequate respond CBC clinical management stable maintenance 4207 7814 11,420
21 cost adequate respond 2nd line hospitalized care 125377 2328441 9,737
22 probability adequate respond hospitalization 0.5 0.8 9,538
23 probability risperidone mild respond noncompliance 0 0.2 9,313
24 cost adequate respond 1st line hospitalized care 74019 137464 8,841
25 probability risperidone intolerable adverse events 0 0.2 8,698
26 probability olanzapine suicide attempt 0 0.2 7,028
27 probability clozapine suicide attempt 0 0.2 6,014
28 cost mild respond drug olanzapine 1742 3742 5,461
29 probability risperidone mild respond noncompliance acute relapse 0.6 0.9 4,170
30 cost mild respond CBC clinical management acute relapse 12320 22880 3,370
31 cost adequate respond risperidone 4mg 3months 364 2364 2,339
32 cost mild respond drug risperidone 364 2364 2,042
33 cost adequate respond olanzapine 10mg 3 month 2742 3742 1,984
34 cost adequate respond CBC clinical management acute relapse 12320 22880 1,040
35 probability risperidone suicide death 0.3 0.5 954
36 probability clozapine suicide death 0.3 0.5 365
37 probability olanzapine suicide death 0.3 0.5 285
38 cost suicide attempt 11123 20658 134














*P_OL_DO: probability of drop out for patients with olanzapine / EV: expected value 
 




*P_RI_DO: probability of drop out for patients with risperidone / EV: expected value 
 
c) One-way sensitivity analysis on the probability of drop out for risperidone 
 
 
*P_RI_IAR: probability of inadequate respond for patients with risperidone / EV: expected value 
 
d) One-way sensitivity analysis on the probability inadequate respond for risperidone 
 74
 [Appendix X] Sensitivity Analysis on cost of hospitalized care for the 2nd line respondent with the 
adequate respond, Net Monetary Benefit (WTP=5,000) 
 
 Cost of hospitalized care for the 2




















[Appendix XI] Types of distribution 
 













[Appendix XII] The input parameters in the PSA 
 
 The first year     
Index Description Parameter. 1 Parameter. 2 Type Option Help/Explanation 
1 olanzapine drop out 614 116 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
2 Olanzapine continue 614 498 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
3 olanzapine adequate respond 277 50 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
4 olanzapine mild respond 277 69 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 





277 158 Beta 1 Param 1 = n; Param 2 = r. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
6 olanzapine intolerable AE 336 32 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
7 olanzapine tolerable AE 336 304 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
8 olanzapine noncompliance 682 96 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
9 olanzapine compliance 682 586 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 






0,6 0.9 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 







0,6 0.9 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 







1.8113858674 16.6721433918 Beta 2 
Param 1 = alpha; Param 2 = beta. Option: 1 = 







1.8113858674 16.6721433918 Beta 2 
Param 1 = alpha; Param 2 = beta. Option: 1 = 





acute relapse 2+ 
0.0752 0.1128 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 






0.0752 0.1128 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
16 adequate respond hospitalized 3.286 1.769 Beta 2 
Param 1 = alpha; Param 2 = beta. Option: 1 = 
Integer parameters only; 2 = Real-numbered 
parameters 
17 mild respond hospitalized care 3.286 1.769 Beta 2 
Param 1 = alpha; Param 2 = beta. Option: 1 = 
Integer parameters only; 2 = Real-numbered 
parameters 
18 olanzapine suicide attempt 783 10 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
19 risperidone drop out 603 133 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
20 risperidone continue 603 470 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
21 risperidone adequate respond 275 62 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
22 risperidone mild respond 275 55 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 





275 158 Beta 1 Param 1 = n; Param 2 = r. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
24 risperidone intolerable AE 341 33 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
25 risperidone 341 308 Beta 1 Param 1 = n; Param 2 = r. Option: 1 = Integer 
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tolerable AE parameters only; 2 = Real-numbered parameters
26 risperidone noncompliance 679 78 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
27 risperidone compliance 679 601 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 






0.6 0.9 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 







0.6 0.9 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 







1.2426153598 2.1618102834 Beta 2 
Param 1 = alpha; Param 2 = beta. Option: 1 = 







1.2426153598 2.1618102834 Beta 2 
Param 1 = alpha; Param 2 = beta. Option: 1 = 





acute relapse 2+ 
0.0752 0.1128 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 






0.0752 0.1128 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
34 clozapine acute relapse 0.6 0.9 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
35 clozapine acute relapse 2+ 0.0752 0.1128 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
36 risperidone suicide attempt 777 14 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters





74019.414 137464.626 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 






125377.602 232844.118 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
40 cost suicide attempt 11123.763 20658,417 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
41 cost suicide death 3438.799 6386.341 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 


















4207.910 7814.690 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 








12320.280 22880.520 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 







10402.686 19319.274 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 







12320.280 22880.520 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
48 mild respond CBC acute relapse 12320.280 22880.520 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 






10402.686 19319.274 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 






74019.414 137464.626 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 






125377.602 232844.118 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 






51170.700 95031.300 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
53 
cost acute stage 
hospitalization 
2nd 
102341.400 190062.600 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
54 cost drop out 2+ 4.5000000000 0.0000018942 Gamma - Param 1 = alpha; Param 2 = lambda 
 
 The second to the fifth year    
Index Description Param. 1 Param. 2 Type Option Help/Explanation 
1 olanzapine drop out 614 116 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
2 olanzapine continue 614 498 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
3 olanzapine adequate respond 277 50 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
4 olanzapine mild respond 277 69 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 





277 158 Beta 1 Param 1 = n; Param 2 = r. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
6 olanzapine intolerable AE 336 32 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
7 olanzapine tolerable AE 336 304 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
8 olanzapine noncompliance 682 96 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
9 olanzapine compliance 682 586 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 






0.6 0.9 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 







0.6 0.9 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 







1.8113858674 16.6721433918 Beta 2 
Param 1 = alpha; Param 2 = beta. Option: 1 = 







1.8113858674 16.6721433918 Beta 2 
Param 1 = alpha; Param 2 = beta. Option: 1 = 





acute relapse 2+ 
0.0752 0.1128 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 






0.0752 0.1128 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
16 adequate respond hospitalized 3.286 1.769 Beta 2 
Param 1 = alpha; Param 2 = beta. Option: 1 = 
Integer parameters only; 2 = Real-numbered 
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parameters 
17 mild respond hospitalized care 3.286 1.769 Beta 2 
Param 1 = alpha; Param 2 = beta. Option: 1 = 
Integer parameters only; 2 = Real-numbered 
parameters 
18 olanzapine suicide attempt 783 10 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
19 risperidone drop out 603 133 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
20 risperidone continue 603 470 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
21 risperidone adequate respond 275 62 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
22 risperidone mild respond 275 55 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 





275 158 Beta 1 Param 1 = n; Param 2 = r. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
24 risperidone intolerable AE 341 33 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
25 risperidone tolerable AE 341 308 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
26 risperidone noncompliance 679 78 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters
27 risperidone compliance 679 601 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 






0.6 0.9 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 







0.6 0.9 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 







1.2426153598 2.1618102834 Beta 2 
Param 1 = alpha; Param 2 = beta. Option: 1 = 







1.2426153598 2.1618102834 Beta 2 
Param 1 = alpha; Param 2 = beta. Option: 1 = 





acute relapse 2+ 
0.0752 0.1128 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 






0.0752 0.1128 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
34 clozapine acute relapse 0.6 0.9 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
35 clozapine acute relapse 2+ 0.0752 0.1128 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
36 risperidone suicide attempt 777 14 Beta 1 
Param 1 = n; Param 2 = r. Option: 1 = Integer 
parameters only; 2 = Real-numbered parameters





74019.414 137464.626 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 






125377.602 232844.118 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
40 cost suicide attempt 11123.763 20658.417 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
41 cost suicide death 3438.799 6386.341 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 



















4207.910 7814.690 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 








12320.280 22880.520 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 







10402.686 19319.274 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 






12320.280 22880.520 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
48 mild respond CBC acute relapse 12320.280 22880.520 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 






10402.686 19319.274 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 






74019.414 137464.626 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 






125377.602 232844.118 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 






51170.700 95031.300 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
53 
cost acute stage 
hospitalization 
2nd 
102341.400 190062.600 Uniform 2 
Param 1 = Low Value; Param 2 = High Value. 
Option: 1 = Integer parameters only; 2 = Real-
numbered parameters 
54 cost drop out 2+ 4.5000000000 0.0000018942 Gamma - Param 1 = alpha; Param 2 = lambda 
 
 
 
 
 
 
 
 
 
 
 
 
 81
